삼성서울병원

Ko En
의료진 검색
찾으실 의료진명을 입력하여 검색해주세요.

혈액종양내과 안진석 교수

진료분야
폐암, 유방암
진료일정 04 月
날짜
월
01
화
02
수
03
목
04
금
05
토
06
일
07
월
08
화
09
수
10
목
11
금
12
토
13
일
14
월
15
화
16
수
17
목
18
금
19
토
20
일
21
월
22
화
23
수
24
목
25
금
26
토
27
일
28
월
29
화
30
오전
오후
진료일정 05 月
날짜
수
01
목
02
금
03
토
04
일
05
월
06
화
07
수
08
목
09
금
10
토
11
일
12
월
13
화
14
수
15
목
16
금
17
토
18
일
19
월
20
화
21
수
22
목
23
금
24
토
25
일
26
월
27
화
28
수
29
목
30
금
31
오전
오후
본원외래 본원클리닉 본원육아상담 암병원외래 암병원클리닉 암병원육아상담

학력

학력
2003.02 가톨릭대학교 대학원 의학과 박사학위 취득
1996.02 서울대학교 대학원 의학과 석사학위 취득
1988.02 서울대학교 의과대학 졸업

경력

경력
2011.04 ~현재 삼성서울병원 혈액종양내과 교수
2019.04 ~ 2021.03 삼성서울병원 암병원 통원치료센터장
2019.04 ~ 2021.03 삼성서울병원 혈액종양내과분과장
2016.01 ~ 2019.03 삼성서울병원 암병원 암치유센터장
2015.03 ~ 2017.03 삼성서울병원 유방암 센터장
2005.05 ~ 2011.03 삼성서울병원 혈액종양내과 부교수
1997.03 ~ 2005.04 한림대학교 의과대학 전임강사, 조교수, 부교수
2003.09 ~ 2004.08 미국 밴더빌트대학 암센터 Post-doc fellow
1996.03 ~ 1997.02 서울대학교병원 혈액종양내과 전임의
1992.05 ~ 1996.02 서울대학교병원 내과 전공의
1988.03 ~ 1989.02 서울대학교병원 인턴

학회활동

학회활동
2010.01 ~ 현재 한국 호스피스 완화의료학회
2006.01 ~ 현재 한국임상암학회
2005.01 ~ 현재 대한폐암학회
1998.01 ~ 현재 대한항암요법연구회
1996.01 ~ 현재 대한내과학회
1994.01 ~ 현재 대한암학회
논문
  • CANCER-AM CANCER SOC 2024 10.1002/cncr.35175 Immune checkpoint inhibitor use and the incidence of hepatitis B virus reactivation or immune-related hepatitis in non-small cell lung cancer patients with chronic hepatitis B Hong, J; Lee, J; Park, S; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Sinn, DH; Ahn, MJ
    View PubMed
  • CANCER RES TREAT 2024 10.4143/crt.2023.461 First-Line Alectinib vs. Brigatinib in Advanced Non-Small Cell Lung Cancer with ALKRearrangement: Real-World Data Jeon, Y; Park, S; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ
    View PubMed
  • THER ADV MED ONCOL 2024 10.1177/17588359231225029 A nationwide real-world study for evaluation of effectiveness and safety of T-DM1 in patients with HER2-positive metastatic breast cancer in Korea (KCSG BR19-15) Baek, SK; Jeong, JH; Jung, K; Ahn, HK; Kim, MH; Sohn, J; Park, IH; Ahn, JS; Lee, DW; Im, SA; Sim, SH; Lee, KS; Kim, JH; Shim, HJ; Chae, Y; Koh, SJ; Lee, H; Lee, J; Byun, JH; Seol, Y; Lee, EM; Jee, HJ; An, H; Park, EB; Suh, YJ; Lee, KE; Park, YH
    View PubMed
  • TRANSL LUNG CANCER R 2023 10.21037/tlcr-23-643 Effectiveness and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in non-small cell lung cancer (NSCLC) Choi, DH; Jung, HA; Park, S; Sun, JM; Ahn, JS; Ahn, MJ; Lee, SH
    View PubMed
  • BREAST 2023 10.1016/j.breast.2023.103594 Benefit of postoperative regional nodal irradiation in patients receiving preoperative systemic therapy with docetaxel/carboplatin/trastuzumab/ pertuzumab for HER2-positive breast cancer Kim, N; Kim, JY; Park, W; Cho, WK; Kim, TG; Im, YH; Ahn, JS; Lee, JE; Nam, SJ; Kim, SW; Yu, J; Chae, BJ; Lee, SK; Ryu, JM; Park, YH; Kim, H
    View PubMed
  • ESMO OPEN 2023 10.1016/j.esmoop.2023.102068 Dacomitinib in EGFR-mutant non-small-cell lung cancer with brain metastasis: a single-arm, phase II study Jung, HA; Park, S; Lee, SH; Ahn, JS; Ahn, MJ; Sun, JM
    View PubMed
  • INT J MOL SCI 2023 10.3390/ijms242115576 A Retrospective Exploratory Analysis for Serum Extracellular Vesicles Reveals APRIL (TNFSF13), CXCL13, and VEGF-A as Prognostic Biomarkers for Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Jung, HH; Kim, JY; Cho, EY; Lee, JE; Kim, SW; Nam, SJ; Park, YH; Ahn, JS; Im, YH
    View PubMed
  • J CACHEXIA SARCOPENI 2023 10.1002/jcsm.13367 Obesity paradox in patients with non-small cell lung cancer undergoing immune checkpoint inhibitor therapy Lee, JH; Kang, B; Ahn, JS; Guallar, E; Cho, J; Lee, HY
    View PubMed
  • NAT COMMUN 2023 10.1038/s41467-023-42900-4 Dostarlimab or pembrolizumab plus chemotherapy in previously untreated metastatic non-squamous non-small cell lung cancer: the randomized PERLA phase II trial Lim, SM; Peters, S; Granados, ALO; Pinto, GDJ; Fuentes, CS; Lo Russo, G; Schenker, M; Ahn, JS; Reck, M; Szijgyarto, Z; Huseinovic, N; Zografos, E; Buss, E; Stjepanovic, N; ODonnell, S; de Marinis, F
    View PubMed
  • CANCERS 2023 10.3390/cancers15225450 Real-World Outcomes of Immunotherapy in Second- or Later-Line Non-Small Cell Lung Cancer with Actionable Genetic Alterations Jun, S; Park, S; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Cho, J; Jung, HA
    View PubMed
  • CANCERS 2023 10.3390/cancers15194720 Comprehensive Clinical Characterization of Decade-Long Survivors of Metastatic Breast Cancer Shin, J; Kim, JY; Oh, JM; Lee, JE; Kim, SW; Nam, SJ; Park, W; Park, YH; Ahn, JS; Im, YH
    View PubMed
  • RADIAT ONCOL 2023 10.1186/s13014-023-02357-7 Impact of high dose radiotherapy for breast tumor in locoregionally uncontrolled stage IV breast cancer: a need for a risk-stratified approach Kim, N; Kim, H; Park, W; Cho, WK; Kim, TG; Im, YH; Ahn, JS; Park, YH; Kim, JY
    View PubMed
  • CANCER RES TREAT 2023 10.4143/crt.2023.403 Expanded Access Program Pralsetinib in Advanced Non-Small Cell Lung Cancer with Rearranged during Transfection (RET) Gene Rearrangement Jeon, Y; Jung, HA; Park, S; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, SH
    View PubMed
  • CANCER-AM CANCER SOC 2023 10.1002/cncr.35059 Biomarker-driven phase 2 umbrella trial: Clinical efficacy of olaparib monotherapy and combination with ceralasertib (AZD6738) in small cell lung cancer Park, S; Kim, YJ; Min, YJ; Mortimer, PGS; Kim, HJ; Smith, SA; Dean, E; Jung, HA; Sun, JM; Park, WY; Ahn, JS; Ahn, MJ; Lee, SH; Park, K
    View PubMed
  • J THORAC ONCOL 2023 10.1016/j.jtho.2023.05.027 Longitudinal Monitoring of Circulating Tumor DNA From Plasma in Patients With Curative Resected Stages I to IIIA EGFR-Mutant Non-Small Cell Lung Cancer Jung, HA; Ku, BM; Kim, YJ; Park, S; Sun, JM; Lee, SH; Ahn, JS; Cho, JH; Kim, HK; Choi, YS; Choi, YL; Shin, SH; Jeong, BH; Um, SW; Kim, H; Kim, K; Ahn, MJ; Kim, J
    View PubMed
  • CLIN CANCER RES 2023 10.1158/1078-0432.CCR-22-3901 BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non-Small Cell Lung Cancer Lim, SM; Fujino, T; Lee, GH; Kim, C; Lee, YH; Kim, DW; Ahn, JS; Mitsudomi, T; Jin, TG; Lee, SY
    View PubMed
  • TRANSL LUNG CANCER R 2023 10.21037/tlcr-23-160 Real-world clinical evidence of lazertinib use in acquired EGFR T790M mutated non-small cell lung cancer Park, S; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ; Sun, JM
    View PubMed
  • CANCERS 2023 10.3390/cancers15133431 Real World Experience of Second-Line Treatment Strategies after Palbociclib and Letrozole: Overall Survival in Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Kim, JY; Shin, J; Ahn, JS; Park, YH; Im, YH
    View PubMed
  • CANCERS 2023 10.3390/cancers15133435 Progesterone Receptor Expression Level Predicts Prognosis of Estrogen Receptor-Positive/HER2-Negative Young Breast Cancer: A Single-Center Prospective Cohort Study Kwak, Y; Jang, SY; Choi, JY; Lee, H; Shin, DS; Park, YH; Kim, JY; Ahn, JS; Chae, BJ; Yu, J; Lee, JE; Kim, SW; Nam, SJ; Ryu, JM
    View PubMed
  • EXP MOL MED 2023 10.1038/s12276-023-01030-z Genomic characteristics of triple negative apocrine carcinoma: a comparison to triple negative breast cancer Kim, JY; Park, S; Cho, EY; Lee, JE; Jung, HH; Chae, BJ; Kim, SW; Nam, SJ; Cho, SY; Park, YH; Ahn, JS; Lee, S; Im, YH
    View PubMed
  • SUPPORT CARE CANCER 2023 10.1007/s00520-023-07779-3 Efficacy of the PRO-CTCAE mobile application for improving patient participation in symptom management during cancer treatment: a randomized controlled trial Lee, M; Kang, D; Kang, E; Kim, S; Kim, Y; Ahn, JS; Park, S; Lee, YY; Oh, D; Noh, JM; Cho, JH
    View PubMed
  • J THORAC ONCOL 2023 10.1016/j.jtho.2023.03.024 Programmed Death-Ligand 1 Copy Number Alteration as an Adjunct Biomarker of Response to Immunotherapy in Advanced NSCLC Hong, TH; Bang, YH; Joe, CY; Hwang, S; Lee, B; Lee, N; Park, S; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Choi, YL; Lee, SH
    View PubMed
  • CANCER RES TREAT 2023 10.4143/crt.2022.1360 A Phase II Trial of S-1 and Oxaliplatin in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane (KCSG-BR07-03) Lee, DW; Keam, B; Lee, KS; Ahn, JH; Sohn, J; Ahn, JS; Lee, MH; Kim, JH; Lee, KE; Kim, HJ; Kim, SY; Park, YH; Ock, CY; Lee, KH; Han, SW; Kim, SB; Im, YH; Chung, HC; Oh, D; Im, SA
    View PubMed
  • CANCER RES TREAT 2023 10.4143/crt.2022.388 EGFR Mutation-Positive Unresectable Stage III Non-Squamous Lung Cancer Is Associated with a High Incidence of Brain Metastasis Kim, H; Park, S; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ
    View PubMed
  • CANCER RES TREAT 2023 10.4143/crt.2022.1344 The Role of Brain Radiotherapy before First-Line Afatinib Therapy, Compared to Gefitinib or Erlotinib, in Patients with EGFR-Mutant Non-Small Cell Lung Cancer Jung, HA; Park, S; Lee, SH; Ahn, JS; Ahn, MJ; Sun, JM
    View PubMed
  • J BREAST CANCER 2023 10.4048/jbc.2023.26.e17 Prognostic Impact of Elevation of Cancer Antigen 15-3 (CA15-3) in Patients With Early Breast Cancer With Normal Serum CA15-3 Level Ryu, JM; Kang, DB; Cho, JH; Lee, JE; Kim, SW; Nam, SJ; Lee, SK; Kim, YJ; Im, YH; Ahn, JS; Park, YH; Kim, JY; Lee, HYJ; Kang, MR; Yu, JH
    View PubMed
  • JAMA NETW OPEN 2023 10.1001/jamanetworkopen.2023.5822 Cardiac Safety and Efficacy of SB3 Trastuzumab Biosimilar for ERBB2-Positive Early Breast Cancer: Secondary Analysis of a Randomized Clinical Trial Pivot, X; Cortes, J; Luftner, D; Lyman, GH; Curigliano, G; Bondarenko, IM; Ahn, JH; Im, SA; Litwiniuk, M; Shparyk, YV; Ho, GF; Kislov, NV; Wojtukiewicz, M; Sarosiek, T; Chae, YS; Ahn, JS; Jang, H; Kim, S; Lee, J; Yoon, Y
    View PubMed
  • ADV SCI 2023 10.1002/advs.202204378 Intracellular Adhesion Molecule-1 Improves Responsiveness to Immune Checkpoint Inhibitor by Activating CD8(+) T Cells Lee, SH; Kim, Y; Jeon, BN; Kim, G; Sohn, J; Yoon, Y; Kim, S; Kim, Y; Kim, H; Cha, HG; Lee, NE; Yang, HYS; Chung, JY; Jeong, AR; Kim, YY; Kim, SG; Seo, Y; Park, S; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Park, H; Yoon, KW
    View PubMed
  • JAMA NETW OPEN 2023 10.1001/jamanetworkopen.2023.2002 Trends in Survival Rates of Non-Small Cell Lung Cancer With Use of Molecular Testing and Targeted Therapy in Korea, 2010-2020 Chi, SA; Yu, H; Choi, YL; Park, S; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Choi, DH; Kim, K; Jung, HA; Park, K
    View PubMed
  • FRONT ONCOL 2023 10.3389/fonc.2023.1146934 Lymphocyte-activating gene 3 expression in tumor cells predicts immune checkpoint inhibitor response in triple negative breast cancer Kim, JY; Kim, J; Cho, EY; Park, YH; Ahn, JS; Kim, KM; Im, YH
    View PubMed
  • J IMMUNOTHER CANCER 2023 10.1136/jitc-2022-005509 Clonal expansion of resident memory T cells in peripheral blood of patients with non-small cell lung cancer during immune checkpoint inhibitor treatment Kim, H; Park, S; Han, KY; Lee, N; Kim, H; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Lee, SH; Park, WY
    View PubMed
  • J THORAC ONCOL 2023 10.1016/j.jtho.2022.10.008 A Phase 2 Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumors (KCSG LU17-21) Jung, HA; Kim, M; Kim, HS; Kim, JH; Choi, YH; Cho, J; Park, JH; Park, KU; Ku, BM; Park, S; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • CANCER RES TREAT 2023 10.4143/crt.2022.264 Five-Year Overall Survival and Prognostic Factors in Patients with Lung Cancer: Results from the Korean Association of Lung Cancer Registry (KALC-R) 2015 Jeon, DS; Kim, HC; Kim, SH; Kim, TJ; Kim, HK; Moon, MH; Beck, KS; Suh, YG; Song, CH; Ahn, JS; Lee, JE; Lim, JU; Jeon, JH; Jung, KW; Jung, CY; Cho, JS; Choi, YD; Hwang, SS; Choi, CM; Korean Assoc Lung Canc; Korea Cent Canc Registry
    View PubMed
  • CANCER RES TREAT 2023 10.4143/crt.2021.1603 Osimertinib Combined with Systemic Chemotherapy for EGFR Mutant, T790M-Negative, Non-Small Cell Lung Cancer Patients Who Develop Leptomeningeal Metastases with Extracranial Progression to Prior EGFR TKI Kim, HR; Jo, H; Kim, H; Hong, J; Park, S; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ
    View PubMed
  • INT J RADIAT ONCOL 2023 10.1016/j.ijrobp.2022.07.018 Association of T Cell Senescence with Radiation Pneumonitis in Patients with Non-small Cell Lung Cancer Kim, KH; Pyo, H; Lee, H; Oh, D; Noh, JM; Ahn, YC; Kim, CG; Yoon, HI; Lee, J; Park, S; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ku, BM; Shin, EC; Ahn, MJ
    View PubMed
  • CANCER MED-US 2022 10.1002/cam4.5460 Transcriptional upregulation of CXCL13 is correlated with a favorable response to immune checkpoint inhibitors in lung adenocarcinoma Park, S; Cha, H; Kim, HS; Lee, B; Kim, S; Kim, TM; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Park, WY; Lee, SH
    View PubMed
  • CANCERS 2022 10.3390/cancers14194839 Long-Term Breast Cancer Outcomes of Pregnancy-Associated Breast Cancer (PABC) in a Prospective Cohort Jo, H; Park, S; Kim, HR; Kim, H; Hong, J; Lee, JE; Yu, J; Chae, BJ; Lee, SK; Ryu, JM; Oh, SY; Choi, SJ; Kim, JY; Ahn, JS; Im, YH; Nam, EM; Nam, SJ; Park, YH
    View PubMed
  • CLIN CANCER RES 2022 10.1158/1078-0432.CCR-22-0879 Clinical, Pathologic, and Molecular Prognostic Factors in Patients with Early-Stage EGFR-Mutant NSCLC br Jung, HA; Lim, J; Choi, YL; Lee, SH; Joung, JG; Jeon, YJ; Choi, JW; Shin, S; Cho, JH; Kim, HK; Choi, YS; Zo, JI; Shim, YM; Park, S; Sun, JM; Ahn, JS; Ahn, MJ; Han, JH; Park, WY; Kim, J; Park, K
    View PubMed
  • CANCER RES TREAT 2022 10.4143/crt.2021.1103 Real-World Evidence of Trastuzumab, Pertuzumab, and Docetaxel Combination as a First-Line Treatment for Korean Patients with HER2-Positive Metastatic Breast Cancer Lee, YP; Lee, MS; Kim, H; Kim, JY; Ahn, JS; Im, YH; Park, YH
    View PubMed
  • CANCER RES TREAT 2022 10.4143/crt.2021.901 Real World Evidence of Neoadjuvant Docetaxel/Carboplatin/Trastuzumab/ Pertuzumab (TCHP) in Patients with HER2-Positive Early or Locally Advanced Breast Cancer: A Single-Institutional Clinical Experience Kim, JY; Nam, SJ; Lee, JE; Yu, J; Chae, BJ; Lee, SK; Ryu, JM; Ahn, JS; Im, YH; Kim, SW; Park, YH
    View PubMed
  • ISCIENCE 2022 10.1016/j.isci.2022.105358 Cellular plasticity and immune microenvironment of malignant pleural effusion are associated with EGFR-TKI resistance in non-small-cell lung carcinoma Jeong, HO; Lee, H; Kim, H; Jang, J; Kim, S; Hwang, T; Choi, DWY; Kim, HS; Lee, N; Lee, YM; Park, S; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, SM; Lee, SH
    View PubMed
  • J AM ACAD DERMATOL 2022 10.1016/j.jaad.2021.10.047 Efficacy of a tailored moisturizer for reducing chemotherapy-induced skin dryness in breast cancer patients: A randomized controlled clinical trial Kang, D; Kim, N; Im, YH; Park, YH; Kim, JY; Park, H; Kim, E; Zhao, D; Guallar, E; Ahn, JS; Cho, J
    View PubMed
  • J THORAC ONCOL 2022 10.1016/j.jtho.2022.04.001 Bevacizumab Plus Atezolizumab After Progression on Atezolizumab Monotherapy in Pretreated Patients With NSCLC: An Open-Label, Two-Stage, Phase 2 Trial Lee, J; Koh, J; Kim, HK; Hong, S; Kim, K; Park, S; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • J CLIN ONCOL 2022 10.1200/JCO.21.02010 Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non-Small-Cell Lung Cancer Park, S; Ock, CY; Kim, H; Pereira, S; Park, S; Ma, M; Choi, S; Kim, S; Shin, S; Aum, BJ; Paeng, K; Yoo, D; Cha, H; Park, S; Suh, KJ; Jung, HA; Kim, SH; Kim, YJ; Sun, JM; Chung, JH; Ahn, JS; Ahn, MJ; Lee, JS; Park, K; Song, SY; Bang, YJ; Choi, YL; Mok, TS; Lee, SH
    View PubMed
  • CLIN CANCER RES 2022 10.1158/1078-0432.CCR-21-3646 Continuation of Pembrolizumab with Additional Chemotherapy after Progression with PD-1/PD-L1 Inhibitor Monotherapy in Patients with Advanced NSCLC: A Randomized, Placebo-Controlled Phase II Study Jung, HA; Park, S; Choi, YL; Lee, SH; Ahn, JS; Ahn, MJ; Sun, JM
    View PubMed
  • FRONT ONCOL 2022 10.3389/fonc.2022.903372 Improved Prediction of Survival Outcomes Using Residual Cancer Burden in Combination With Ki-67 in Breast Cancer Patients Underwent Neoadjuvant Chemotherapy Kim, JY; Oh, JM; Lee, SK; Yu, J; Lee, JE; Kim, SW; Nam, SJ; Park, YH; Ahn, JS; Kim, K; Im, YH
    View PubMed
  • INT J RADIAT ONCOL 2022 10.1016/j.ijrobp.2022.02.003 Dynamics of Circulating Immune Cells During Chemoradiotherapy in Patients with Non-Small Cell Lung Cancer Support Earlier Administration of Anti-PD-1/PD-L1 Kim, KH; Pyo, H; Lee, H; Oh, D; Noh, JM; Ahn, YC; Yoon, HI; Moon, H; Lee, J; Park, S; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ku, BM; Ahn, MJ; Shin, EC
    View PubMed
  • EUR J CANCER 2022 10.1016/j.ejca.2022.03.034 Durvalumab with chemoradiotherapy for limited-stage small-cell lung cancer Park, S; Noh, JM; Choi, YL; Chi, SA; Kim, K; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ; Sun, JM
    View PubMed
  • CANCER MED-US 2022 10.1002/cam4.4663 Longitudinal monitoring by next-generation sequencing of plasma cell-free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors Kwon, M; Ku, BM; Olsen, S; Park, S; Lefterova, M; Odegaard, J; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • J THORAC ONCOL 2022 10.1016/j.jtho.2021.11.025 A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors Cho, BC; Han, JY; Kim, SW; Lee, KH; Cho, EK; Lee, YG; Kim, DW; Kim, JH; Lee, GW; Lee, JS; Shim, BY; Kim, JS; Chun, SH; Lee, SS; Kim, HR; Hong, MH; Ahn, JS; Sun, JM; Lee, Y; Lee, DH; Kang, JA; Lee, N; Kwon, MJ; Espenschied, C; Yablonovitch, A; Ahn, MJ
    View PubMed
  • SCI REP-UK 2022 10.1038/s41598-022-09542-w Temporal patterns of chronic disease incidence after breast cancer: a nationwide population-based cohort study Kang, D; Kang, M; Hong, YS; Park, J; Lee, J; Seo, HJ; Kim, DW; Ahn, JS; Park, YH; Lee, SK; Shin, DW; Guallar, E; Cho, J
    View PubMed
  • J MED SYST 2022 10.1007/s10916-022-01800-8 Development and Validation of Digital Health Technology Literacy Assessment Questionnaire Yoon, J; Lee, M; Ahn, JS; Oh, D; Shin, SY; Chang, YJ; Cho, J
    View PubMed
  • ONCOLOGY-BASEL 2022 10.1159/000516813 Role of Circulating Tumor DNA Profiling in Patients with Non-Small Cell Lung Cancer Treated with EGFR Inhibitor Ku, BM; Kim, YJ; Park, D; Lee, SH; Ahn, JS; Park, K; Ahn, MJ; Sun, JM
    View PubMed
  • INVEST NEW DRUG 2022 10.1007/s10637-021-01121-6 ERK inhibitor ASN007 effectively overcomes acquired resistance to EGFR inhibitor in non-small cell lung cancer Ku, BM; Heo, JY; Kim, J; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • CANCER RES TREAT 2022 10.4143/crt.2020.1200 Validation of the Korean Version of the Patient-Reported Outcomes Measurement Information System 29 Profile V2.1 among Cancer Survivors Kang, D; Kim, Y; Lim, J; Yoon, J; Kim, S; Kang, E; Nam, H; Shim, S; Lee, M; Bok, H; Lee, SW; Shin, SY; Ahn, JS; Oh, D; Cho, J
    View PubMed
  • CANCER RES TREAT 2022 10.4143/crt.2021.306 Long-term Survival in Non-Small Cell Lung Cancer Patients with Metachronous Brain-Only Oligorecurrence Who Underwent Definitive Treatment Kim, H; Park, S; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • BLOOD CANCER J 2021 10.1038/s41408-021-00595-0 Risk of non-Hodgkin lymphoma in breast cancer survivors: a nationwide cohort study Kang, D; Yoon, SE; Shin, D; Lee, J; Hong, YS; Lee, SK; Lee, JE; Park, YH; Ahn, JS; Guallar, E; Kim, WS; Lee, J; Kim, SJ; Cho, J
    View PubMed
  • CANCERS 2021 10.3390/cancers13225835 Real-World Data from a Refractory Triple-Negative Breast Cancer Cohort Selected Using a Clinical Data Warehouse Approach Kim, H; Kim, HJ; Kim, H; Kim, HR; Jo, H; Hong, J; Kim, R; Kim, JY; Ahn, JS; Im, YH; Lee, SK; Kim, H; Shin, SY; Park, YH
    View PubMed
  • CANCERS 2021 10.3390/cancers13215260 Elevated Level of Nerve Growth Factor (NGF) in Serum-Derived Exosomes Predicts Poor Survival in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy Jung, HH; Kim, JY; Cho, EY; Oh, JM; Lee, JE; Kim, SW; Nam, SJ; Park, YH; Ahn, JS; Im, YH
    View PubMed
  • EUR J CANCER 2021 10.1016/j.ejca.2021.09.037 Extrapulmonary tuberculosis in patients with RET fusion-positive non-small cell lung cancer treated with pralsetinib: A Korean single-centre compassionate use experience Lee, YP; Jeong, BH; Eun, Y; Kang, CI; Park, S; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Sun, JM
    View PubMed
  • TRANSL LUNG CANCER R 2021 10.21037/tlcr-21-691 Molecular subtypes of small cell lung cancer transformed from adenocarcinoma after EGFR tyrosine kinase inhibitor treatment Hwang, S; Hong, TH; Park, S; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Choi, YL; Lee, SH
    View PubMed
  • FRONT ONCOL 2021 10.3389/fonc.2021.759150 Which Clinicopathologic Parameters Suggest Primary Resistance to Palbociclib in Combination With Letrozole as the First-Line Treatment for Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer? Kim, JY; Oh, JM; Park, YH; Ahn, JS; Im, YH
    View PubMed
  • TRANSL LUNG CANCER R 2021 10.21037/tlcr-21-531 Real-time autOmatically updated data warehOuse in healThcare (ROOT): an innovative and automated data collection system Jung, HA; Jeong, O; Chang, DK; Park, S; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Park, K
    View PubMed
  • SUPPORT CARE CANCER 2021 10.1007/s00520-021-06473-6 Who is more likely to adopt and comply with the electronic patient-reported outcome measure (ePROM) mobile application? A real-world study with cancer patients undergoing active treatment Lee, M; Kang, D; Kim, S; Lim, J; Yoon, J; Kim, Y; Shim, S; Kang, E; Ahn, JS; Cho, J; Shin, SY; Oh, D
    View PubMed
  • J KOREAN MED SCI 2021 10.3346/jkms.2021.36.e212 Patient-Reported Outcomes Measurement Information System: Translation and Linguistic Validation of Six Profile Domains for Korean Adults Kim, Y; Yoon, J; Kim, N; Lee, M; Kang, D; Park, HY; Oh, D; Sung, KS; Suh, GY; Ahn, JS; Cho, J
    View PubMed
  • CLIN BREAST CANCER 2021 10.1016/j.clbc.2020.12.013 Ventriculoperitoneal Shunt for CNS Metastasis in Breast Cancer: Clinical Outcomes Based on Intrinsic Subtype Kim, HK; Lee, HS; Heo, MH; Kim, JY; Ahn, JS; Im, YH; Lee, JI; Park, YH
    View PubMed
  • BREAST CANCER RES TR 2021 10.1007/s10549-021-06310-8 Prediction of pathologic complete response to neoadjuvant chemotherapy using machine learning models in patients with breast cancer Kim, JY; Jeon, E; Kwon, S; Jung, H; Joo, S; Park, Y; Lee, SK; Lee, JE; Nam, SJ; Cho, EY; Park, YH; Ahn, JS; Im, YH
    View PubMed
  • NANOMED-NANOTECHNOL 2021 10.1016/j.nano.2021.102415 Therapeutic efficacy of cancer vaccine adjuvanted with nanoemulsion loaded with TLR7/8 agonist in lung cancer model Koh, J; Kim, S; Lee, SN; Kim, SY; Kim, JE; Lee, KY; Kim, MS; Heo, JY; Park, YM; Ku, BM; Sun, JM; Lee, SH; Ahn, JS; Park, K; Yang, S; Ha, SJ; Lim, YT; Ahn, MJ
    View PubMed
  • FRONT ONCOL 2021 10.3389/fonc.2021.596364 Deep Learning-Based Prediction Model for Breast Cancer Recurrence Using Adjuvant Breast Cancer Cohort in Tertiary Cancer Center Registry Kim1, JY; Lee, YS; Yu, J; Park, Y; Lee, SK; Lee, M; Lee, JE; Kim, SW; Nam, SJ; Park, YH; Ahn, JS; Kang, M; Im, YH
    View PubMed
  • CANCER 2021 10.1002/cncr.33571 High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean lung liquid versus invasive biopsy program Park1, S; Olsen, S; Ku, BM; Lee, MS; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Choi, YL; Ahn, MJ
    View PubMed
  • J KOREAN NEUROSURG SOC 2021 10.3340/jkns.2020.0135 Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer with Brain Metastasis : The Role of Gamma Knife Radiosurgery Lee1, MH; Cho, KR; Choi, JW; Kong, DS; Seol, HJ; Nam, DH; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Lee, JI
    View PubMed
  • FRONT ONCOL 2021 10.3389/fonc.2021.653243 The Role of Chemotherapy in Patients With HER2-Negative Isolated Locoregional Recurrence of Breast Cancer: A Multicenter Retrospective Cohort Study Lee1, K; Sim, SH; Kang, EJ; Seo, JH; Chae, H; Lee, KS; Kim, JY; Ahn, JS; Im, YH; Park, S; Park, YH; Park, IH
    View PubMed
  • DIAGNOSTICS 2021 10.3390/diagnostics11020370 Local Laboratory Testing of Germline BRCA Mutations vs. Myriad: A Single-Institution Experience in Korea Hong1, J; Lee, J; Kwon, M; Kim, JY; Kim, JW; Ahn, JS; Im, YH; Park, YH
    View PubMed
  • EUR J IMMUNOL 2021 10.1002/eji.202048966 Tumor infiltrated immune cell types support distinct immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer Ku1, BM; Kim, Y; Lee, KY; Kim, SY; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • TRANSL LUNG CANCER R 2021 10.21037/tlcr-20-1128 Comprehensive evaluation of the clinical utility of plasma EGFR test in non-small cell lung cancer patients with acquired resistance to first-line EGFR inhibitors Kim1, H; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Sun, JM
    View PubMed
  • CLIN APPL THROMB-HEM 2021 10.1177/1076029620979575 Treatment Patterns and Clinical Outcomes in Korean Cancer Patients With Venous Thromboembolism: A Retrospective Cohort Study Bang1, SM; Kang, JH; Hong, MH; Ahn, JS; Oh, SY; Baek, JH; Choi, YJ; Shin, SH; Kim, YJ; Gil, H; Park, HE; Lee, J; Park, EL
    View PubMed
  • IMMUNE NETW 2020 10.4110/in.2020.20.e48 Immunological Characteristics of Hyperprogressive Disease in Patients with Non-small Cell Lung Cancer Treated with Anti-PD-1/PD-L1 Abs Kim1, KH; Hur, JY; Koh, J; Cho, J; Ku, BM; Koh, JY; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ; Shin, EC
    View PubMed
  • J THORAC ONCOL 2020 10.1016/j.jtho.2020.06.018 Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status Lee1, J; Choi, YL; Han, J; Park, S; Jung, HA; Su, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • SCI REP-UK 2020 10.1038/s41598-020-76130-1 Regulatory -(FoxP3(+)) T cells and TGF-beta predict the response to anti-PD-1 immunotherapy in patients with non-small cell lung cancer Koh1, J; Hur, JY; Lee, KY; Kim, MS; Heo, JY; Ku, BM; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • ANN ONCOL 2020 10.1016/j.annonc.2020.06.017 A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy Park1, S; Lee, MH; Seong, M; Kim, ST; Kang, JH; Cho, BC; Lee, KH; Cho, EK; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • BIOLOGY-BASEL 2020 10.3390/biology9100326 Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations Are They Different from Those with Common EGFR Mutations? Jung1, HA; Park, S; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Park, K
    View PubMed
  • TRANSL LUNG CANCER R 2020 10.21037/tlcr-20-379 The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer Jung1, HA; Woo, SY; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Sun, JM
    View PubMed
  • J IMMUNOTHER CANCER 2020 10.1136/jitc-2020-001199 Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity Hong1, TH; Cha, H; Shim, JH; Lee, B; Chung, J; Lee, C; Kim, NKD; Choi, YL; Hwang, S; Lee, Y; Park, S; Jung, HA; Kim, JY; Park, YH; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, SH; Park, WY
    View PubMed
  • CANCER RES TREAT 2020 10.4143/crt.2020.278 EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation Park1, S; Ku, BM; Jung, HA; Sun, JM; Ahn, JS; Lee, SH; Park, K; Ahn, MJ
    View PubMed
  • J THORAC DIS 2020 10.21037/jtd-20-1671 Characteristics of female lung cancer in Korea analysis of Korean National Lung Cancer Registry Lim1, JU; Han, S; Kim, HC; Choi, CM; Jung, CY; Cho, DG; Jeon, JH; Lee, JE; Ahn, JS; Kim, Y; Choi, YD; Suh, YG; Kim, JE; Won, YJ; Kim, YC; Park, CK; Kim, SJ
    View PubMed
  • MOL CANCER RES 2020 10.1158/1541-7786.MCR-19-1108 Clinical Characteristics and Exploratory Genomic Analyses of Germline BRCA1 or BRCA2 Mutations in Breast Cancer Park1, S; Lee, E; Park, S; Lee, S; Nam, SJ; Kim, SW; Lee, JE; Yu, JH; Kim, JY; Ahn, JS; Im, YH; Park, WY; Park, K; Park, YH
    View PubMed
  • SCI REP-UK 2020 10.1038/s41598-020-70168-x Metabolic radiogenomics in lung cancer associations between FDG PET image features and oncogenic signaling pathway alterations Kim1, G; Kim, J; Cha, H; Park, WY; Ahn, JS; Ahn, MJ; Park, K; Park, YJ; Choi, JY; Lee, KH; Lee, SH; Moon, SH
    View PubMed
  • LUNG CANCER 2020 10.1016/j.lungcan.2020.05.033 Ten-year patient journey of stage III non-small cell lung cancer patients A single-center, observational, retrospective study in Korea (Realtime autOmatically updated data warehOuse in healTh care; UNIVERSE-ROOT study) Jung1, HA; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Park, K
    View PubMed
  • ANN ONCOL 2020 10.1016/j.annonc.2020.04.478 Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study Mok1, T; Camidge, DR; Gadgeel, SM; Rosell, R; Dziadziuszko, R; Kim, DW; Perol, M; Ou, SHI; Ahn, JS; Shaw, AT; Bordogna, W; Smoljanovic, V; Hilton, M; Ruf, T; Noe, J; Peters, S
    View PubMed
  • LUNG CANCER 2020 10.1016/j.lungcan.2020.05.035 Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer Jung1, HA; Noh, JM; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Pyo, H; Ahn, YC; Park, K
    View PubMed
  • EXPERT OPIN INV DRUG 2020 10.1080/13543784.2020.1804855 Phase I clinical trial of KML001 monotherapy in patients with advanced solid tumors Kim1, S; Kim, S; Park, YS; Park, JO; Lim, HY; Ahn, JS; Lee, J; Sun, JM; Kang, WK; Han, R; Kim, J; Ahn, MJ
    View PubMed
  • BREAST CANCER RES TR 2020 10.1007/s10549-020-05874-1 Prognostication of a 13-immune-related-gene signature in patients with early triple-negative breast cancer Kim1, JY; Jung, HH; Sohn, I; Woo, SY; Cho, H; Cho, EY; Lee, JE; Kim, SW; Nam, SJ; Park, YH; Ahn, JS; Im, YH
    View PubMed
  • J THORAC DIS 2020 10.21037/jtd.2019.08.29 Are there any ethnic differences in the efficacy and safety of immune checkpoint inhibitors for treatment of lung cancer? Lee1, J; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • CANCER RES TREAT 2020 10.4143/crt.2019.713 Ramosetron versus Palonosetron in Combination with Aprepitant and Dexamethasone for the Control of Highly-Emetogenic Chemotherapy-Induced Nausea and Vomiting Kang1, JH; Kwon, JH; Lee, YG; Park, KU; An, HJ; Sohn, J; Seol, YM; Lee, H; Yun, HJ; Ahn, JS; Yang, JH; Song, H; Koo, DH; Kim, JY; Kim, GM; Kim, HJ
    View PubMed
  • ANN ONCOL 2020 10.1016/j.annonc.2020.04.004 HLA-corrected tumor mutation burden and homologous recombination de fi ciency for the prediction of response to PD -(L)1 blockade in advanced non -small -cell lung cancer patients Shim1, JH; Kim, HS; Cha, H; Kim, S; Kim, TM; Anagnostou, V; Choi, YL; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Park, WY; Lee, SH
    View PubMed
  • EXPERT OPIN PHARMACO 2020 10.1080/14656566.2020.1798932 Evaluating entrectinib as a treatment option for non-small cell lung cancer Lee1, JY; Park, S; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • CANCER 2020 10.1002/cncr.32809 Genomic landscape of acquired resistance to third-generation EGFR tyrosine kinase inhibitors in EGFR T790M-mutant non-small cell lung cancer Lee1, J; Kim, HS; Lee, B; Kim, HK; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, SH
    View PubMed
  • EUR J CANCER 2020 10.1016/j.ejca.2020.03.029 Outstanding clinical efficacy of PD-1/PD-L1 inhibitors for pulmonary pleomorphic carcinoma Lee1, J; La Choi, Y; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Sun, JM
    View PubMed
  • NAT COMMUN 2020 10.1038/s41467-020-16164-1 Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma Kim1, N; Kim, HK; Lee, K; Hong, Y; Cho, JH; Choi, JW; Lee, J; Suh, YL; Ku, BM; Eum, HH; Choi, S; Choi, YL; Joung, JG; Park, WY; Jung, HA; Sun, JM; Lee, SN; Ahn, JS; Park, K; Ahn, MJ; Lee, HO
    View PubMed
  • J PAIN SYMPTOM MANAG 2020 Reliability and Validity of the Korean Language Version of the US National Cancer Institute?s Patient -Reported Outcomes Common Terminology Criteria for Adverse Events Yoon1, J; Sim, SH; Kang, D; Han, G; Kim, Y; Ahn, J; Oh, D; Lee, ES; Kong, SY; Cho, J; Mitchell, SA
    View PubMed
  • CANCERS 2020 10.3390/cancers12051306 Clinical Characteristics of Korean Breast Cancer Patients Who Carry Pathogenic Germline Mutations in Both BRCA1 and BRCA2: A Single-Center Experience Hur1, JY; Kim, JY; Ahn, JS; Im, YH; Lee, J; Kwon, M; Park, YH
    View PubMed
  • CLIN LUNG CANCER 2020 10.1016/j.cllc.2019.11.006 Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests Byeon1, S; Lee, B; Park, WY; Choi, YL; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, SH
    View PubMed
  • IN VIVO 2020 10.21873/invivo.11920 Characteristics and Clinical Outcomes of Non-small Cell Lung Cancer Patients in Korea With MET Exon 14 Skipping Hur1, JY; Ku, BM; Shim, JH; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • SUPPORT CARE CANCER 2020 10.1007/s00520-019-04982-z Impact of a topical lotion, CG428, on permanent chemotherapy-induced alopecia in breast cancer survivors: a pilot randomized double-blind controlled clinical trial (VOLUME RCT) Kang1, D; Kim, IR; Park, YH; Im, YH; Zhao, D; Guallar, E; Ahn, JS; Cho, J
    View PubMed
  • INVEST NEW DRUG 2020 10.1007/s10637-019-00795-3 Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer Ku1, BM; Bae, YH; Lee, KY; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • J CLIN ONCOL 2020 10.1200/JCO.19.00457 Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation?Positive Non?Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study Yang1, JCH; Kim, SW; Kim, DW; Lee, JS; Cho, BC; Ahn, JS; Lee, DH; Kim, TM; Goldman, JW; Natale, RB; Brown, AP; Collins, B; Chmielecki, J; Vishwanathan, K; Mendoza-Naranjo, A; Ahn, MJ
    View PubMed
  • J CLIN ONCOL 2020 10.1200/JCO.19.00931 Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09) Cho1, JH; Lim, SH; An, HJ; Kim, KH; Park, KU; Kang, EJ; Choi, YH; Ahn, MS; Lee, MH; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • Cancer Med 2020 10.1002/cam4.2868 PD-1 inhibitors for non-small cell lung cancer patients with special issues: Real-world evidence Byeon1, S; Cho, JH; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • CANCER RES TREAT 2020 10.4143/crt.2019.186 Clinical Characteristics and Outcomes of Non-small Cell Lung Cancer Patients with HER2 Alterations in Korea Lee1, K; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahm, MJ
    View PubMed
  • LUNG CANCER 2020 10.1016/j.lungcan.2019.10.015 Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer Ou1, SHI; Gadgeel, SM; Barlesi, F; Yang, JCH; De Petris, L; Kim, DW; Govindan, R; Dingemans, AM; Crino, L; Lena, H; Popat, S; Ahn, JS; Dansin, E; Mitry, E; Muller, B; Bordogna, W; Balas, B; Morcos, PN; Shaw, AT
    View PubMed
  • Oncoimmunology 2020 10.1080/2162402X.2020.1722023 Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment Kim1, KH; Hur, JY; Cho, J; Ku, BM; Koh, J; Koh, JY; Sun, JM; Lee, SN; Ahn, JS; Park, K; Ahn, MJ; Shin, EC
    View PubMed
  • BMC OPHTHALMOL 2020 10.1186/s12886-019-1285-9 Markedly increased ocular side effect causing severe vision deterioration after chemotherapy using new or investigational epidermal or fibroblast growth factor receptor inhibitors Shin1, E; Lim, DH; Han, JS; Nam, D; Park, K; Ahn, MJ; Kang, WK; Lee, JY; Ahn, JS; Lee, SH; Sun, JM; Jung, HA; Chung, TY
    View PubMed
  • LANCET ONCOL 2019 10.1016/S1470-2045(19)30504-2 Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study Ahn1, MJ; Han, JY; Lee, KH; Kim, SW; Kim, DW; Lee, YG; Cho, EK; Kim, JH; Lee, GW; Lee, JS; Min, YJ; Kim, JS; Lee, SS; Kim, HR; Hong, MH; Ahn, JS; Sun, JM; Kim, HT; Lee, DH; Kim, S; Cho, BC
    View PubMed
  • LANCET ONCOL 2019 10.1016/S1470-2045(19)30565-0 Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial Park1, YH; Kim, TY; Kim, GM; Kang, SY; Park, IH; Kim, JH; Lee, KE; Ahn, HK; Lee, MH; Kim, HJ; Kim, HJ; Lee, JI; Koh, SJ; Kim, JY; Lee, KH; Sohn, J; Kim, SB; Ahn, JS; Im, YH; Jung, KH; Im, SA
    View PubMed
  • INT J CANCER 2019 10.1002/ijc.32235 Improved treatment outcome of pembrolizumab in patients with nonsmall cell lung cancer and chronic obstructive pulmonary disease Shin1, SH; Park, HY; Im, Y; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, HY; Lee, SH
    View PubMed
  • EUR J CANCER 2019 10.1016/j.ejca.2019.08.001 Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing Kim1, HS; Cha, H; Kim, JH; Park, WY; Choi, YL; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, SH
    View PubMed
  • CANCER RES TREAT 2019 10.4143/crt.2018.704 Report of the Korean Association of Lung Cancer Registry (KALC-R), 2014 Choi1, CM; Kim, HC; Jung, CY; Cho, DG; Jeon, JH; Lee, JE; Ahn, JS; Kim, SJ; Kim, Y; Choi, YD; Suh, YG; Kim, JE; Lee, B; Won, YJ; Kim, YC
    View PubMed
  • J THORAC ONCOL 2019 10.1016/j.jtho.2019.05.033 Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor Kim1, Y; Kim, CH; Lee, HY; Lee, SH; Kim, HS; Lee, S; Cha, H; Hong, S; Kim, K; Seo, SW; Sun, JM; Ahn, MJ; Ahn, JS; Park, K
    View PubMed
  • J THORAC ONCOL 2019 10.1016/j.jtho.2019.05.014 DNA Damage Response and Repair Pathway Alteration and Its Association With Tumor Mutation Burden and Platinum-Based Chemotherapy in SCLC Park1, S; Lee, H; Lee, B; Lee, SH; Sun, JM; Park, WY; Ahn, JS; Ahn, MJ; Park, K
    View PubMed
  • NAT COMMUN 2019 10.1038/s41467-019-12159-9 DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load Jung1, H; Kim, HS; Kim, JY; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Esteller, M; Lee, SH; Choi, JK
    View PubMed
  • KOREAN JOURNAL OF INTERNAL MEDICINE 2019 10.3904/kjim.2017.226 Clinical activity of fulvestrant in metastatic breast cancer previously treated with endocrine therapy and/or chemotherapy Heo1, MH; Kim, HK; Lee, H; Kim, JY; Ahn, JS; Im, YH; Park, YH
    View PubMed
  • SCI REP-UK 2019 10.1038/s41598-019-48674-4 Predictive and Prognostic Value of F-18-fluorodeoxyglucose Uptake Combined with Thymidylate Synthase Expression in Patients with Advanced Non-Small Cell Lung Cancer Moon1, SH; Sun, JM; Ahn, JS; Park, K; Kim, BT; Lee, KH; Ahn, MJ; Choi, JY
    View PubMed
  • J CLIN ONCOL 2019 10.1200/JCO.2017.77.3184 Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial Cho1, J; Kim, HS; Ku, BM; Choi, YL; Cristescu, R; Han, J; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • LUNG CANCER 2019 10.1016/j.lungcan.2019.05.024 Paired genomic analysis of squamous cell carcinoma transformed from EGFR-mutated lung adenocarcinoma Park1, S; Shim, JH; Lee, B; Cho, I; Park, WY; Kim, Y; Lee, SH; Choi, YL; Han, J; Ahn, JS; Ahn, MJ; Park, K; Sun, JM
    View PubMed
  • JAMA Oncol 2019 10.1001/jamaoncol.2019.0339 Subcutaneous vs Intravenous Trastuzumab for Patients With ERBB2-Positive Early Breast Cancer Final Analysis of the HannaH Phase 3 Randomized Clinical Trial Jackisch1, C; Stroyakovskiy, D; Pivot, X; Ahn, JS; Melichar, B; Chen, SC; Meyenberg, C; Al-Sakaff, N; Heinzmann, D; Hegg, R
    View PubMed
  • J IMMUNOTHER CANCER 2019 10.1186/s40425-019-0609-x Paired whole exome and transcriptome analyses for the Immunogenomic changes during concurrent chemoradiotherapy in esophageal squamous cell carcinoma Park1, S; Joung, JG; Min, YW; Nam, JY; Ryu, D; Oh, D; Park, WY; Lee, SH; Choi, YL; Ahn, JS; Ahn, MJ; Park, K; Sun, JM
    View PubMed
  • J CANCER RES CLIN 2019 10.1007/s00432-019-02889-0 Impact of EGFR mutation on the clinical efficacy of PD-1 inhibitors in patients with pulmonary adenocarcinoma Cho1, JH; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Sun, JM
    View PubMed
  • CLIN LUNG CANCER 2019 10.1016/j.cllc.2018.12.020 Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor Lee1, J; Sun, JM; Lee, SH; Ahn, JS; Park, K; Choi, YL; Ahn, MJ
    View PubMed
  • CANCER RES TREAT 2019 10.4143/crt.2018.151 Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea Byeon1, S; Kim, Y; Lim, SW; Cho, JH; Park, S; Lee, J; Sun, JM; Choi, YL; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • CANCER RES TREAT 2019 10.4143/crt.2018.324 A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13 Yoo1, KH; Lee, SJ; Cho, J; Lee, KH; Park, KU; Kim, KH; Cho, EK; Choi, YH; Kim, HR; Kim, HG; Ahn, HJ; Lee, HY; Yun, HJ; Kang, JH; Jeong, J; Choi, MY; Jung, SH; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • CLIN CANCER RES 2019 10.1158/1078-0432.CCR-18-1449 The First-week Proliferative Response of Peripheral Blood PD-1(+)CD8(+) T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors Kim1, KH; Cho, J; Ku, BM; Koh, J; Sun, JM; Lee, SH; Ahn, JS; Cheon, J; Min, YJ; Park, SH; Park, K; Ahn, MJ; Shin, EC
    View PubMed
  • LUNG CANCER 2019 10.1016/j.lungcan.2019.01.012 Repeat biopsy procedures and T790M rates after afatinib, gefitinib, or erlotinib therapy in patients with lung cancer Lee1, K; Kim, Y; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Choi, YL; Sun, JM
    View PubMed
  • CANCER RES TREAT 2019 10.4143/crt.2018.366 Salvage Concurrent Chemo-radiation Therapy for Loco-regional Recurrence Following Curative Surgery of Non-small Cell Lung Cancer Lee1, KH; Ahn, YC; Pyo, H; Noh, JM; Park, SG; Kim, TG; Lee, E; Nam, H; Lee, H; Sun, JM; Ahn, JS; Ahn, MJ; Park, K
    View PubMed
  • CANCER RES TREAT 2019 10.4143/crt.2018.125 EGFR Mutation Is Associated with Short Progression-Free Survival in Patients with Stage III Non-squamous Cell Lung Cancer Treated with Concurrent Chemoradiotherapy Park1, SE; Noh, JM; Kim, YJ; Lee, HS; Cho, JH; Lim, SW; Ahn, YC; Pyo, H; Choi, YL; Han, J; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • CANCER RES TREAT 2019 10.4143/crt.2018.117 Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib Kim1, Y; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Sun, JM
    View PubMed
  • CANCER RES TREAT 2019 10.4143/crt.2018.262 Early Decline in Left Ventricular Ejection Fraction Can Predict Trastuzumab-Related Cardiotoxicity in Patients with Breast Cancer: A Study Using 13 Years of Registry Data Kim1, EK; Cho, J; Kim, JY; Chang, SA; Park, SJ; Choi, JO; Lee, SC; Ahn, JS; Park, SW; Im, YH; Jeon, ES; Park, YF
    View PubMed
  • CANCER RES TREAT 2019 10.4143/crt.2018.342 Discordance of the PAM50 Intrinsic Subtypes Compared with Immunohistochemistry-Based Surrogate in Breast Cancer Patients: Potential Implication of Genomic Alterations of Discordance Kim1, HK; Park, KH; Kim, Y; Park, SE; Lee, HS; Lim, SW; Cho, JH; Kim, JY; Lee, JE; Ahn, JS; Im, YH; Yu, JH; Park, YH
    View PubMed
  • ONCOLOGIST 2019 10.1634/theoncologist.2018-0184 Permanent Chemotherapy-Induced Alopecia in Patients with Breast Cancer: A 3-Year Prospective Cohort Study Kang1, D; Kim, IR; Choi, EK; Im, YH; Park, YH; Ahn, JS; Lee, JE; Nam, SJ; Lee, HK; Park, JH; Lee, DY; Lacouture, ME; Guallar, E; Cho, J
    View PubMed
  • EUR J NUCL MED MOL I 2019 10.1007/s00259-018-4138-5 Correlations between metabolic texture features, genetic heterogeneity, and mutation burden in patients with lung cancer Moon1, SH; Kim, J; Joung, JG; Cha, H; Park, WY; Ahn, JS; Ahn, MJ; Park, K; Choi, JY; Lee, KH; Kim, BT; Lee, SH
    View PubMed
  • ONCOL LETT 2019 10.3892/ol.2018.9754 Clinical features and prognosis of breast cancer with gastric metastasis Hong1, J; Kim, Y; Cho, J; Lim, SW; Park, SE; Kim, HK; Lee, H; Cho, SY; Kim, JY; Ahn, JS; Im, YH; Park, YH
    View PubMed
  • CLIN NUCL MED 2019 10.1097/RLU.0000000000002394 Pretreatment Tumor 18F-FDG Uptake Improves Risk Stratification Beyond RECIST 1.1 in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer FDG Uptake and Risk Stratification Moon1, SH; Sun, JM; Ahn, JS; Park, K; Ahn, MJ; Choi, JY
    View PubMed
  • J THORAC ONCOL 2019 10.1016/j.jtho.2018.10.150 Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC Kim1, Y; Lee, B; Shim, JH; Lee, SH; Park, WY; Choi, YL; Sun, JM; Ahn, JS; Ahn, MJ; Park, K
    View PubMed
  • MEDICINE 2019 10.1097/MD.0000000000014278 Sedation for terminally ill cancer patients A multicenter retrospective cohort study in South Korea Kim1, YS; Song, HN; Ahn, JS; Koh, SJ; Ji, JH; Hwang, IG; Yun, J; Kwon, JH; Kang, JH
    View PubMed
  • HERED CANCER CLIN PR 2019 10.1186/s13053-018-0103-3 The association between non-breast and ovary cancers and BRCA mutation in first- and second-degree relatives of high-risk breast cancer patients: a large-scale study of Koreans Kim1, H; Choi, DH; Park, W; Im, YH; Ahn, JS; Park, YH; Nam, SJ; Kim, SW; Lee, JE; Yu, JH; Lee, SK; Jung, BY
    View PubMed
  • CANCER RES TREAT 2019 10.4143/crt.2018.138 Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-Mutated Non-small Cell Lung Cancer Lee1, J; Shim, JH; Park, WY; Kim, HK; Sun, JM; Lee, SN; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • BREAST CANCER RES TR 2019 10.1007/s10549-018-4981-x A nomogram to predict pathologic complete response (pCR) and the value of tumor-infiltrating lymphocytes (TILs) for prediction of response to neoadjuvant chemotherapy (NAC) in breast cancer patients Hwang1, HW; Jung, H; Hyeon, J; Park, YH; Ahn, JS; Im, YH; Nam, SJ; Kim, SW; Lee, JE; Yu, JH; Lee, SK; Choi, M; Cho, SY; Cho, EY
    View PubMed
  • BMC CANCER 2019 10.1186/s12885-018-5258-9 Does guideline non-adherence result in worse clinical outcomes for hormone receptor-positive and HER2-negative metastatic breast cancer in premenopausal women?: result of an institution database from South Korea Kim1, HK; Lee, SH; Kim, YJ; Park, SE; Lee, HS; Lim, SW; Cho, JH; Kim, JY; Ahn, JS; Im, YH; Yu, JH; Park, YH
    View PubMed
  • J BREAST CANC 2018 10.4048/jbc.2018.21.e48 PIK3CA Mutations and Neoadjuvant Therapy Outcome in Patients with Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: A Sequential Analysis Seo1, Y; Park, YH; Ahn, JS; Im, YH; Nam, SJ; Cho, SY; Cho, EY
    View PubMed
  • INT J CANCER 2018 10.1002/ijc.31651 A phase II trial of the pan-HER inhibitor poziotinib, in patients with HER2-positive metastatic breast cancer who had received at least two prior HER2-directed regimens: results of the NOV120101-203 trial Park1, YH; Lee, KH; Sohn, JH; Lee, KS; Jung, KH; Kim, JH; Lee, KH; Ahn, JS; Kim, TY; Kim, GM; Park, IH; Kim, SB; Kim, SH; Han, HS; Im, YH; Ahn, JH; Kim, JY; Kang, J; Im, SA
    View PubMed
  • EUR J CANCER 2018 10.1016/j.ejca.2018.08.004 Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label, three-arm, randomised phase II trial (FLAG study) Kim1, JY; Im, SA; Jung, KH; Ro, J; Sohn, J; Kim, JH; Park, YH; Kim, TY; Kim, SB; Lee, KS; Kim, GM; Kim, SH; Kim, S; Ahn, JS; Lee, KH; Ahn, JH; Park, IH; Im, YH
    View PubMed
  • CLIN BREAST CANCER 2018 10.1016/j.clbc.2018.04.010 Effect of Body Mass Index on Survival in Breast Cancer Patients According to Subtype, Metabolic Syndrome, and Treatment Cho1, WK; Choi, DH; Park, W; Cha, H; Nam, SJ; Kim, SW; Lee, JE; Yu, J; Im, YH; Ahn, JS; Park, YH; Kim, JY; Ahn, S
    View PubMed
  • BREAST CANCER RES TR 2018 10.1007/s10549-018-4858-z Validation of the new AJCC eighth edition of the TNM classification for breast cancer with a single-center breast cancer cohort Kim1, JY; Lim, JE; Jung, HH; Cho, SY; Cho, EY; Lee, SK; Yu, JH; Lee, JE; Kim, SW; Nam, SJ; Park, YH; Ahn, JS; Im, YH
    View PubMed
  • LUNG CANCER 2018 10.1016/j.lungcan.2018.08.003 Continuation of gefitinib beyond progression in patients with EGFR mutation-positive non-small-cell lung cancer: A phase II single-arm trial Lim1, SW; Park, S; Kim, Y; Cho, JH; Park, SE; Lee, H; Kim, HK; Kim, SM; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • J THORAC ONCOL 2018 10.1016/j.jtho.2018.05.026 Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice Park1, S; Ahn, BC; Lim, SW; Sun, JM; Kim, HR; Hong, MH; Lee, SH; Ahn, JS; Park, K; La Choi, Y; Cho, BC; Ahn, MJ
    View PubMed
  • J THORAC ONCOL 2018 10.1016/j.jtho.2018.04.038 Transient Asymptomatic Pulmonary Opacities During Osimertinib Treatment and its Clinical Implication Lee1, H; Lee, HY; Sun, JM; Lee, SN; Kim, Y; Park, SE; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • LUNG CANCER 2018 10.1016/j.lungcan.2018.06.009 Efficacy of mesna, doxorubicin, ifosfamide, and dacarbazine (MAID) in patients with advanced pulmonary pleomorphic carcinoma Lee1, J; Jung, HA; Kim, Y; Choi, S; Han, J; Choi, YL; Lee, SH; Ahn, JS; Park, K; Sun, JM
    View PubMed
  • J BREAST CANC 2018 10.4048/jbc.2018.21.2.206 Which Patients with Left Breast Cancer Should be Candidates for Heart-Sparing Radiotherapy? Cho1, WK; Park, W; Choi, DH; Cha, H; Nam, SJ; Kim, SW; Lee, JE; Yu, J; Im, YH; Ahn, JS; Park, YH; Kim, JY
    View PubMed
  • Clin Pharmacol Drug Dev 2018 10.1002/cpdd.427 Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC Tan1, EH; Lim, WT; Ahn, MJ; Ng, QS; Ahn, JS; Tan, DSW; Sun, JM; Han, M; Payumo, FC; Mckee, K; Yin, W; Credi, M; Agarwal, S; Jac, J; Park, K
    View PubMed
  • ASIA-PAC J CLIN ONCO 2018 10.1111/ajco.12696 Inadequate treatment practices for pain relief and adverse eventmanagement in cancer patients across 10 countries/regions in Asia: a call for greater efforts to improve standards for patient care Ho1, KY; Ahn, JS; Calimag, MM; Chao, TC; Kim, YC; Moon, H; Tho, LM; Xia, ZJ; You, DR
    View PubMed
  • Oncoimmunology 2018 10.1080/2162402X.2018.1466768 Clinical implication of tumor mutational burden in patients with HER2-positive refractory metastatic breast cancer Park1, SE; Park, K; Lee, E; Kim, JY; Ahn, JS; Im, YH; Lee, C; Jung, H; Cho, SY; Park, WY; Cristescu, R; Park, YH
    View PubMed
  • LUNG CANCER 2018 10.1016/j.lungcan.2018.02.020 Afatinib in heavily pretreated advanced NSCLC patients who progressed following prior gefitinib or erlotinib: Compassionate use program in Korea Choi1, MK; Ahn, JS; Kim, YC; Cho, BC; Oh, IJ; Kim, SW; Lee, JS; Kim, JH; Ahn, MJ; Park, K
    View PubMed
  • AM J HEMATOL 2018 10.1002/ajh.25043 Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study Gambacorti-Passerini1, C; Orlov, S; Zhang, L; Braiteh, F; Huang, HQ; Esaki, T; Horibe, K; Ahn, JS; Beck, JT; Edenfield, WJ; Shi, YK; Taylor, M; Tamura, K; Van Tine, BA; Wu, SJ; Paolini, J; Selaru, P; Kim, TM
    View PubMed
  • NAT COMMUN 2018 10.1038/s41467-018-04129-4 Multi-omics profiling of younger Asian breast cancers reveals distinctive molecular signatures Kan1, ZY; Ding, Y; Kim, J; Jung, HH; Chung, W; Lal, S; Cho, S; Fernandez-Banet, J; Lee, SK; Kim, SW; Lee, JE; Choi, YL; Deng, S; Kim, JY; Ahn, JS; Sha, Y; Mu, XJ; Nam, JY; Im, YH; Lee, S; Park, WY; Nam, SJ; Park, YH
    View PubMed
  • PLoS One 2018 10.1371/journal.pone.0194730 Acquired resistance to AZD9291 as an upfront treatment is dependent on ERK signaling in a preclinical model Ku1, BM; Choi, MK; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • BRIT J CANCER 2018 10.1038/bjc.2017.465 Pazopanib maintenance after first-line etoposide and platinum chemotherapy in patients with extensive disease small-cell lung cancer: a multicentre, randomised, placebo-controlled Phase II study (KCSG-LU12-07) Sun1, JM; Lee, KH; Kim, BS; Kim, HG; Min, YJ; Yi, SY; Yun, HJ; Jung, SH; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • LUNG CANCER 2018 10.1016/j.lungcan.2018.01.004 Temporal and regional distribution of initial recurrence site in completely resected N1-stage II lung adenocarcinoma: The effect of postoperative adjuvant chemotherapy Park1, BJ; Cho, JH; Lee, JH; Shin, S; Kim, HK; Choi, YS; Zo, JI; Shim, YM; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Kim, J
    View PubMed
  • J BREAST CANC 2018 10.4048/jbc.2018.21.1.91 Breast Cancer Epidemiology of the Working-Age Female Population Reveals Significant Implications for the South Korean Economy Park1, JH; Lee, SK; Lee, JE; Kim, SW; Nam, SJ; Kim, JY; Ahn, JS; Park, W; Yu, J; Park, YH
    View PubMed
  • J THORAC ONCOL 2018 10.1016/j.jtho.2017.10.014 KIF5B-MET Gene Rearrangement with Robust Antitumor Activity in Response to Crizotinib in Lung Adenocarcinoma Cho1, JH; Ku, BM; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • J THORAC ONCOL 2018 10.1016/j.jtho.2017.10.007 Late-Onset Cholecystitis with Cholangitis after Avelumab Treatment in Non-Small Cell Lung Cancer Cho1, JH; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • LUNG CANCER 2018 10.1016/j.lungcan.2017.11.020 Recurrence dynamics after trimodality therapy (Neoadjuvant concurrent chemoradiotherapy and surgery) in patients with stage IIIA (N2) lung cancer Lee1, J; Kim, HK; Park, BJ; Cho, JH; Choi, YS; Zo, JI; Shim, YM; Pyo, H; Ahn, YC; Ahn, JS; Ahn, MJ; Park, K; Kim, J
    View PubMed
  • J THORAC ONCOL 2018 10.1016/j.jtho.2017.10.011 Increased Response Rates to Salvage Chemotherapy Administered after PD-1 /PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer Park1, SE; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Sun, JM
    View PubMed
  • BMC CANCER 2018 10.1186/s12885-017-3965-2 A train the trainer program for healthcare professionals tasked with providing psychosocial support to breast cancer survivors Park1, E; Yoon, J; Choi, EK; Kim, IR; Kang, D; Lee, SK; Lee, JE; Nam, SJ; Ahn, JS; Visser, A; Cho, J
    View PubMed
  • J THORAC ONCOL 2017 10.1016/j.jtho.2017.09.1954 Randomized Phase II Trial Comparing Chemoradiotherapy with Chemotherapy for Completely Resected Unsuspected N2-Positive Non-Small Cell Lung Cancer Sun1, JM; Noh, JM; Oh, D; Kim, HK; Lee, SH; Choi, YS; Pyo, H; Ahn, JS; Jung, SH; Ahn, YC; Kim, J; Ahn, MJ; Zo, JI; Shim, YM; Park, K
    View PubMed
  • NAT COMMUN 2017 10.1038/s41467-017-01470-y Prevalence and detection of low-allele-fraction variants in clinical cancer samples Shin1, HT; Choi, YL; Yun, JW; Kim, NKD; Kim, SY; Jeon, HJ; Nam, JY; Lee, C; Ryu, D; Kim, SC; Park, K; Lee, E; Bae, JS; Son, DS; Joung, JG; Lee, J; Kim, ST; Ahn, MJ; Lee, SH; Ahn, JS; Lee, WY; Oh, BY; Park, YH; Lee, JE; Lee, KH; Kim, HC; Kim, KM; Im, YH; Park, K; Park, PJ; Park, WY
    View PubMed
  • Lancet Respir Med 2017 10.1016/S2213-2600(17)30378-8 Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study Ahn1, MJ; Kim, DW; Cho, BC; Kim, SW; Lee, JS; Ahn, JS; Kim, TM; Lin, CC; Kim, HR; John, T; Kao, S; Goldman, JW; Su, WC; Natale, R; Rabbie, S; Harrop, B; Overend, P; Yang, ZF; Yang, JCH
    View PubMed
  • CANCER RES TREAT 2017 10.4143/crt.2016.442 Role of Adjuvant Thoracic Radiation Therapy and Full Dose Chemotherapy in pN2 Non-small Cell Lung Cancer: Elucidation Based on Single Institute Experience Park1, H; Oh, D; Ahn, YC; Pyo, H; Noh, JM; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Kim, HK; Choi, YS; Kim, J; Zo, JI; Shim, YM
    View PubMed
  • EXPERT REV MOL DIAGN 2017 10.1080/14737159.2017.1372196 An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer Ku1, BM; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • J THORAC ONCOL 2017 10.1016/j.jtho.2017.06.070 Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer Yang1, JCH; Ou, SHI; De Petris, L; Gadgeel, S; Gandhi, L; Kim, DW; Barlesi, F; Govindan, R; Dingemans, AMC; Crino, L; Lena, N; Popat, S; Ahn, JS; Dansin, E; Golding, S; Bordogna, W; Batas, B; Morcos, PN; Zeaiter, A; Shaw, AT
    View PubMed
  • ONCOTARGET 2017 Mutational status of TP53 defines the efficacy of Wee1 inhibitor AZD1775 in KRAS-mutant non-small cell lung cancer Ku1, BM; Bae, YH; Koh, J; Sun, JM; Lee, SSH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • CANCER CHEMOTH PHARM 2017 10.1007/s00280-017-3396-4 Comparison of RECIST to immune-related response criteria in patients with non-small cell lung cancer treated with immune-checkpoint inhibitors Kim1, HK; Heo, MH; Lee, HS; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
    View PubMed
  • Chin J Cancer 2017 10.1186/s40880-017-0241-4 Efficacy and safety of controlled-release oxycodone/naloxone versus controlled-release oxycodone in Korean patients with cancer-related pain: a randomized controlled trial Lee1, KH; Kim, TW; Kang, JH; Kim, JS; Ahn, JS; Kim, SY; Yun, HJ; Eum, YJ; Koh, SA; Kim, MK; Hong, YS; Kim, JE; Lee, GW
    View PubMed
  • BREAST CANCER RES TR 2017 10.1007/s10549-017-4304-7 Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial Cortes1, J; Rugo, HS; Awada, A; Twelves, C; Perez, EA; Im, SA; Gomez-Pardo, P; Schwartzberg, LS; Dieras, V; Yardley, DA; Potter, DA; Mailliez, A; Moreno-Aspitia, A; Ahn, JS; Zhao, C; Hoch, U; Tagliaferri, M; Hannah, AL; O'Shaughnessy, J
    View PubMed
  • ASIA-PAC J CLIN ONCO 2017 10.1111/ajco.12652 Clinical outcomes according to molecular subtypes in stage II-III breast cancer patients treated with neoadjuvant chemotherapy followed by surgery and radiotherapy Kim1, H; Park, W; Huh, SJ; Choi, DH; Noh, JM; Im, YH; Ahn, JS; Park, YH; Nam, SJ; Kim, SW; Lee, JE; Cho, EY
    View PubMed
  • NEW ENGL J MED 2017 10.1056/NEJMoa1704795 Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer Peters1, S; Camidge, DR; Shaw, AT; Gadgeel, S; Ahn, JS; Kim, DW; Ou, SHI; Perol, M; Dziadziuszko, R; Rosell, R; Zeaiter, A; Mitry, E; Golding, S; Balas, B; Noe, J; Morcos, PN; Mok, T
    View PubMed
  • J Pain Res 2017 10.2147/JPR.S140320 Transdermal buprenorphine and fentanyl patches in cancer pain: a network systematic review Ahn1, JS; Lin, J; Ogawa, S; Yuan, C; O'Brien, T; Le, BHC; Bothwell, AM; Moon, H; Hadjiat, Y; Ganapathi, A
    View PubMed
  • BREAST CANCER RES TR 2017 10.1007/s10549-017-4268-7 A prospective randomized controlled trial of hydrating nail solution for prevention or treatment of onycholysis in breast cancer patients who received neoadjuvant/adjuvant docetaxel chemotherapy Kim1, JY; Ok, ON; Seo, JJ; Lee, SH; Ahn, JS; Im, YH; Park, YH
    View PubMed
  • ONCOTARGET 2017 10.18632/oncotarget.17653 Immune signature of metastatic breast cancer: Identifying predictive markers of immunotherapy response Kim1, JY; Lee, E; Park, K; Park, WY; Jung, HH; Ahn, JS; Im, YH; Park, YH
    View PubMed
  • Eur J Cancer. 2017 May;76:205-215. doi: 10.1016/j.ejca.2017.02.011. Epub 2017 Mar 27. Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial Twelves C11, Cortes J2, O'Shaughnessy J3, Awada A4, Perez EA5, Im SA6, Gomez-Pardo P7, Schwartzberg LS8, Dieras V9, Yardley DA10, Potter DA11, Mailliez A12, Moreno-Aspitia A13, Ahn JS14, Zhao C15, Hoch U15, Tagliaferri M15, Hannah AL16, Rugo HS17.
    View PubMed
  • Expert Opin Drug Saf. 2017 Apr;16(4):465-469. doi: 10.1080/14740338.2017.1300656. Epub 2017 Mar 8. EGFR TKI combination with immunotherapy in non-small cell lung cancer Ahn MJ11, Sun JM1, Lee SH1, Ahn JS1, Park K1.
    View PubMed
  • Oncotarget. 2017 Apr 25;8(17):27997-28007. doi: 10.18632/oncotarget.15881. Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes Kim JY11, Lee E2, Park K2, Park WY2, Jung HH3, Ahn JS1, Im YH1,4, Park YH1,4,3.
    View PubMed
  • Expert Opin Pharmacother. 2017 Feb;18(2):225-231. doi: 10.1080/14656566.2017.1285283. Osimertinib for the treatment of non-small cell lung cancer Sun JM11, Lee SH1, Ahn JS1, Park K1, Ahn MJ1.
    View PubMed
  • Oncotarget. 2017 Jan 31;8(5):8693-8706. doi: 10.18632/oncotarget.14414. The effect of androgen receptor expression on clinical characterization of metastatic breast cancer Kim JY11, Park K2, Lee E2, Jung HH3, Ahn JS1, Im YH1,4, Park WY2,5, Park YH1,4,3.
    View PubMed
  • J Thorac Oncol. 2016 Dec;11(12):2051-2052. doi: 10.1016/j.jtho.2016.09.130. Transient Asymptomatic Pulmonary Opacities during Osimertinib Treatment: "Stop or Go" Decision Ahn MJ11, Sun JM2, Lee SH2, Ahn JS2, Park K2.
    View PubMed
  • J Thorac Oncol. 2016 Dec;11(12):2202-2207. doi: 10.1016/j.jtho.2016.07.005. Epub 2016 Jul 14. Do New pN Subclassifications Proposed by IASLC's Lung Cancer Staging Project Agree with ypN Categories after Trimodality Therapy for Initial N2 Disease? Kim H11, Ahn YC2, Pyo H1, Oh D1, Noh JM1, Sun JM3, Ahn JS3, Ahn MJ3, Park K3, Choi YS4, Kim J4, Zo JI4, Shim YM4, Lee M5, Han J5.
    View PubMed
  • Breast Cancer Res Treat. 2016 Dec;160(3):475-489. doi: 10.1007/s10549-016-4008-4. Epub 2016 Oct 11. Assessment of pathologic response and long-term outcome in locally advanced breast cancers after neoadjuvant chemotherapy: comparison of pathologic classification systems Choi M11, Park YH2, Ahn JS2, Im YH2, Nam SJ3, Cho SY4, Cho EY5.
    View PubMed
  • J Thorac Dis. 2016 Nov;8(11):3175-3186. doi: 10.21037/jtd.2016.11.25. The impact of smoking status on radiologic tumor progression patterns and response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations Cha YK11, Lee HY2, Ahn MJ3, Park K3, Ahn JS3, Sun JM3, Choi YL4, Lee KS2.
    View PubMed
  • World Neurosurg. 2016 Nov;95:399-405. doi: 10.1016/j.wneu.2016.08.046. Epub 2016 Aug 24. Outcomes of Gamma Knife Radiosurgery in Combination with Crizotinib for Patients with Brain Metastasis from Non-Small Cell Lung Cancer Choi JW11, Kong DS1, Seol HJ1, Nam DH1, Yoo KH2, Sun JM2, Ahn JS2, Ahn MJ2, Park K2, Lee JI3.
    View PubMed
  • Lung Cancer. 2016 Oct;100:24-29. doi: 10.1016/j.lungcan.2016.07.025. Epub 2016 Jul 26. Value of volume-based early metabolic response in patients with unresectable thymic epithelial tumor Moon SH11, Kim HS2, Cho YS1, Sun JM3, Ahn JS3, Park K3, Kim BT1, Ahn MJ4, Lee KH5.
    View PubMed
  • Cancer Res Treat. 2016 Oct;48(4):1338-1350. Epub 2016 Feb 18. Association between Mutation and Expression of TP53 as a Potential Prognostic Marker of Triple-Negative Breast Cancer Kim JY11, Park K2, Jung HH3, Lee E2, Cho EY4, Lee KH5, Bae SY6, Lee SK6, Kim SW6, Lee JE6, Nam SJ6, Ahn JS1, Im YH1,3, Park YH1,3.
    View PubMed
  • Cancer. 2016 Oct;122(19):3024-31. doi: 10.1002/cncr.30135. Epub 2016 Jun 17. Efficacy and Safety of Dovitinib in Pretreated Patients With Advanced Squamous Non-Small Cell Lung Cancer With FGFR1 Amplification: A Single-Arm, Phase 2 Study Lim SH11, Sun JM1, Choi YL2, Kim HR3, Ahn S2, Lee JY1, Lee SH1, Ahn JS1, Park K1, Kim JH3, Cho BC4, Ahn MJ5.
    View PubMed
  • Cancer Res Treat. 2016 Oct;48(4):1382-1388. Epub 2016 Mar 11. Clinicopathologic Features and Long-Term Outcomes of Elderly Breast Cancer Patients: Experiences at a Single Institution in Korea Kim HK11, Ham JS1, Byeon S1, Yoo KH1, Jung KS1, Song HN1, Cho J1, Lee JY1, Lim SH1, Kim HS1, Kim JY1, Lee JE2, Kim SW2, Nam SJ2, Lee SK2, Bae SY2, Ahn JS1, Im YH1, Park YH1.
    View PubMed
  • Sci Rep. 2016 Sep 8;6:33035. doi: 10.1038/srep33035. Statins affect ETS1-overexpressing triple-negative breast cancer cells by restoring DUSP4 deficiency Jung HH11, Lee SH2, Kim JY2, Ahn JS2, Park YH1,2,3, Im YH2,3.
    View PubMed
  • PLoS One. 2016 Sep 20;11(9):e0163254. doi: 10.1371/journal.pone.0163254. eCollection 2016. Clinicopathological Features and Prognostic Factors Affecting Survival Outcomes in Isolated Locoregional Recurrence of Breast Cancer: Single-Institutional Series Lee MY11, Chang WJ1, Kim HS1, Lee JY1, Lim SH1, Lee JE2, Kim SW2, Nam SJ2, Ahn JS1, Im YH1, Park YH1.
    View PubMed
  • Med Oncol. 2016 Aug;33(8):97. doi: 10.1007/s12032-016-0811-3. Epub 2016 Jul 22. Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis Byeon S11, Ham JS1, Sun JM2, Lee SH2, Ahn JS2, Park K2, Ahn MJ3.
    View PubMed
  • Invest New Drugs. 2016 Aug;34(4):407-15. doi: 10.1007/s10637-016-0350-y. Epub 2016 Apr 5. AZD9291 overcomes T790 M-mediated resistance through degradation of EGFR(L858R/T790M) in non-small cell lung cancer cells Ku BM11, Bae YH1, Koh J1, Sun JM2, Lee SH2, Ahn JS2, Park K2, Ahn MJ3,4.
    View PubMed
  • SCIENTIFIC REPORTS, AUG 22 2016, 6, DOI: 10.1038/srep31804 The relationship between nuclear factor (NF)-kappa B family gene expression and prognosis in triple-negative breast cancer (TNBC) patients receiving adjuvant doxorubicin treatment Kim JY1, Jung HH, Ahn S, Bae S, Lee SK, Kim SW, Lee JE, Nam SJ, Ahn JS, Im YH
    View PubMed
  • Eur J Cancer. 2016 Jul;62:62-75. doi: 10.1016/j.ejca.2016.03.087. Epub 2016 May 20. HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant-adjuvant trastuzumab after 2 years of treatment-free follow-up Jackisch C11, Hegg R2, Stroyakovskiy D3, Ahn JS4, Melichar B5, Chen SC6, Kim SB7, Lichinitser M8, Starosławska E9, Kunz G10, Falcon S11, Chen ST12, Crepelle-Flechais A13, Heinzmann D13, Shing M14, Pivot X15.
    View PubMed
  • Oncotarget. 2016 Jun 14;7(24):36311-36320. doi: 10.18632/oncotarget.8904. Targeted sequencing identifies genetic alterations that confer Primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium) Lim SM11,2, Kim HR1, Cho EK3, Min YJ4, Ahn JS5, Ahn MJ5, Park K5, Cho BC1, Lee JH6, Jeong HC6, Kim EK6, Kim JH2.
    View PubMed
  • Lung Cancer. 2016 Jun;96:48-51. doi: 10.1016/j.lungcan.2016.03.012. Epub 2016 Mar 26. Assessment of objective responses in thymic epithelial tumors using ITMIG modified criteria Kim HS11, Lee JY2, Lim SH2, Sun JM2, Lee SH2, Ahn JS2, Park K2, Ahn MJ3.
    View PubMed
  • Sci Rep. 2016 Jun 24;6:28623. doi: 10.1038/srep28623. Gene Expression Profiling of Breast Cancer Brain Metastasis Lee JY11, Park K2, Lee E2, Ahn T2, Jung HH3, Lim SH1, Hong M4, Do IG4, Cho EY4, Kim DH5, Kim JY1, Ahn JS1, Im YH1,2, Park YH1,3.
    View PubMed
  • J Breast Cancer. 2016 Jun;19(2):169-75. doi: 10.4048/jbc.2016.19.2.169. Epub 2016 Jun 24. Lymph Node Ratio as a Risk Factor for Locoregional Recurrence in Breast Cancer Patients with 10 or More Axillary Nodes Kim SW11, Choi DH2, Huh SJ2, Park W2, Nam SJ3, Kim SW3, Lee JE3, Im YH4, Ahn JS4, Park YH4.
    View PubMed
  • Clin Breast Cancer. 2016 Jun;16(3):e15-21. doi: 10.1016/j.clbc.2015.11.008. Epub 2015 Dec 11. Limited Supraclavicular Radiation Field in Breast Cancer With >= 10 Positive Axillary Lymph Nodes Yu JI11, Park W2, Choi DH1, Huh SJ1, Nam SJ3, Kim SW3, Lee JE3, Kil WH3, Im YH4, Ahn JS4, Park YH4, Cho EY5.
    View PubMed
  • Clin Cancer Res. 2016 May 1;22(9):2139-45. doi: 10.1158/1078-0432.CCR-15-1653. Epub 2015 Dec 14. A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non-Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib Lee JY11, Sun JM1, Lim SH1, Kim HS, Yoo KH1, Jung KS1, Song HN1, Ku BM2, Koh J2, Bae YH2, Lee SH1, Ahn JS1, Park K1, Ahn MJ3.
    View PubMed
  • JOURNAL OF CLINICAL ONCOLOGY, MAR 1 2016, 34(7):768-+, DOI: 10.1200/JCO.2015.65.1042 Consolidation Chemotherapy After Concurrent Chemoradiotherapy in Patients With Stage III Non-Small-Cell Lung Cancer Reply Ahn JS1, Park K
    View PubMed
  • J Clin Oncol. 2016 Mar 1;34(7):661-8. doi: 10.1200/JCO.2015.63.9443. Epub 2015 Nov 23. Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study Ou SH11, Ahn JS2, De Petris L2, Govindan R2, Yang JC2, Hughes B2, Lena H2, Moro-Sibilot D2, Bearz A2, Ramirez SV2, Mekhail T2, Spira A2, Bordogna W2, Balas B2, Morcos PN2, Monnet A2, Zeaiter A2, Kim DW2.
    View PubMed
  • Cancer Imaging. 2016 Mar 16;16:5. doi: 10.1186/s40644-016-0063-7. Volume-based growth tumor kinetics as a prognostic biomarker for patients with EGFR mutant lung adenocarcinoma undergoing EGFR tyrosine kinase inhibitor therapy: a case control study Lee JH11, Lee HY2, Ahn MJ3, Park K3, Ahn JS3, Sun JM3, Lee KS1.
    View PubMed
  • Oncotarget. 2016 Mar 22;7(12):14803-13. doi: 10.18632/oncotarget.7543. The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma Ku BM11, Yi SY2, Koh J1, Bae YH1, Sun JM3, Lee SH3, Ahn JS3, Park K3, Ahn MJ3.
    View PubMed
  • EXPERT OPINION ON BIOLOGICAL THERAPY, MAR 3 2016, 16(3):397-406 , DOI: 10.1517/14712598.2016.1145652 Pembrolizumab for the treatment of non-small cell lung cancer Lim SH1, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ
    View PubMed
  • PLoS One. 2016 Feb 22;11(2):e0149432. doi: 10.1371/journal.pone.0149432. eCollection 2016. The Impacts of Inclusion in Clinical Trials on Outcomes among Patients with Metastatic Breast Cancer (MBC) Lee JY11, Lim SH1, Lee MY1, Kim HS1, Ahn JS1, Im YH1, Park YH1.
    View PubMed
  • BMC Cancer. 2016 Feb 22;16:138. doi: 10.1186/s12885-016-2195-3. Prognostic value of ERBB4 expression in patients with triple negative breast cancer Kim JY11, Jung HH2, Do IG3, Bae S4, Lee SK5, Kim SW6, Lee JE7, Nam SJ8, Ahn JS9, Park YH10,11, Im YH12,13.
    View PubMed
  • Oncotarget. 2016 Feb 9;7(6):6984-93. doi: 10.18632/oncotarget.6874. Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02) Lee JY11, Qing X2, Xiumin W2, Yali B2, Chi S3, Bak SH4, Lee HY5, Sun JM1, Lee SH1, Ahn JS1, Cho EK6, Kim DW7, Kim HR8, Min YJ9, Jung SH3, Park K1, Mao M2, Ahn MJ1.
    View PubMed
  • Oncologist. 2015 Dec;20(12):1440-7. doi: 10.1634/theoncologist.2015-0128. Epub 2015 Oct 28. Ramosetron Versus Ondansetron in Combination With Aprepitant and Dexamethasone for the Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Multicenter, Randomized Phase III Trial, KCSG PC10-21 Kim HJ11, Shin SW2, Song EK3, Lee NR3, Kim JS4, Ahn JS5, Yun HJ6, Cho YH7, Park KU8, Kim SY9, Jang JS10, Kim SW11, Lee HW12, Lee SR13, Kim YS14, Lee SN15, Ko YH16, Kim HJ17, Kang JH18.
    View PubMed
  • Oncotarget. 2015 Dec 22;6(41):43731-42. doi: 10.18632/oncotarget.6192. Mutational profiling of brain metastasis from breast cancer: matched pair analysis of targeted sequencing between brain metastasis and primary breast cancer Lee JY11, Park K2, Lim SH1, Kim HS1, Yoo KH1, Jung KS1, Song HN1, Hong M3, Do IG3, Ahn T2, Lee SK4, Bae SY4, Kim SW4, Lee JE4, Nam SJ4, Kim DH5, Jung HH6, Kim JY1, Ahn JS1, Im YH1, Park YH1.
    View PubMed
  • Clin Breast Cancer. 2015 Dec;15(6):512-8. doi: 10.1016/j.clbc.2015.06.004. Epub 2015 Jun 18. Clinical Outcomes and Prognostic Factors of Pathologic N3 Breast Cancer Treated With Modern Standard Treatments Yu JI11, Park W2, Choi DH1, Huh SJ1, Nam SJ3, Kim SW3, Lee JE3, Kil WH3, Im YH4, Ahn JS4, Park YH4, Cho EY5.
    View PubMed
  • J Thorac Oncol. 2015 Dec;10(12):1800-6. doi: 10.1097/JTO.0000000000000692. A Prospective Phase II Study of Cisplatin and Cremophor EL-Free Paclitaxel (Genexol-PM) in Patients with Unresectable Thymic Epithelial Tumors Kim HS11, Lee JY, Lim SH, Sun JM, Lee SH, Ahn JS, Park K, Moon SH, Ahn MJ.
    View PubMed
  • Lung Cancer. 2015 Nov;90(2):261-6. doi: 10.1016/j.lungcan.2015.08.020. Epub 2015 Sep 4. Pemetrexed plus platinum versus pemetrexed alone in non-small cell lung cancer patients who have progressed after first-line EGFR TKIs Lee SJ11, Sun JM1, Lee SH1, Ahn JS1, Park K1, Ahn MJ2.
    View PubMed
  • J Neurooncol. 2015 Nov;125(2):331-8. doi: 10.1007/s11060-015-1915-x. Epub 2015 Sep 15. Outcome of gamma knife radiosurgery for metastatic brain tumors derived from non-small cell lung cancer Cho KR11, Lee MH1, Kong DS1, Seol HJ1, Nam DH1, Sun JM2, Ahn JS2, Ahn MJ2, Park K2, Kim ST3, Lim do H4, Lee JI5.
    View PubMed
  • Lancet Oncol. 2015 Nov;16(15):1556-68. doi: 10.1016/S1470-2045(15)00332-0. Epub 2015 Oct 22. Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial Perez EA11, Awada A2, O'Shaughnessy J3, Rugo HS4, Twelves C5, Im SA6, Gomez-Pardo P7, Schwartzberg LS8, Dieras V9, Yardley DA10, Potter DA11, Mailliez A12, Moreno-Aspitia A13, Ahn JS14, Zhao C15, Hoch U15, Tagliaferri M15, Hannah AL16, Cortes J17.
    View PubMed
  • Cancer Res Treat. 2015 Oct;47(4):765-73. doi: 10.4143/crt.2014.168. Epub 2015 Jan 13. Impact on Survival of Regular Postoperative Surveillance for Patients with Early Breast Cancer Lee JY11, Lim SH1, Lee MY1, Kim H1, Kim M1, Kim S1, Jung HA1, Sohn I2, Gil WH3, Lee JE3, Kim SW3, Nam SJ3, Ahn JS1, Im YH1, Park YH1.
    View PubMed
  • ONCOTARGET, OCT 13 2015, 6(31), 30929-30938, 10.18632/oncotarget.5131 Low EGFR/MET ratio is associated with resistance to EGFR inhibitors in non-small cell lung cancer Park S1, Langley E, Sun JM, Lockton S, Ahn JS, Jain A, Park K, Singh S, Kim P, Ahn MJ
    View PubMed
  • Cancer Res Treat. 2015 Oct;47(4):645-52. doi: 10.4143/crt.2014.144. Epub 2015 Feb 12. Definitive Bimodality Concurrent Chemoradiotherapy in Patients with Inoperable N2-positive Stage IIIA Non-small Cell Lung Cancer Noh JM11, Ahn YC1, Lee H2, Pyo H1, Kim B1, Oh D1, Park H1, Lee E1, Park K3, Ahn JS3, Ahn MJ3, Sun JM3.
    View PubMed
  • Oncotarget. 2015 Oct 20;6(32):33358-68. doi: 10.18632/oncotarget.5188. The NEXT-1 (Next generation pErsonalized tX with mulTi-omics and preclinical model) trial: prospective molecular screening trial of metastatic solid cancer patients, a feasibility analysis Kim ST11, Lee J1, Hong M2,3, Park K4,5, Park JO1, Ahn T3,4, Park SH1, Park YS1, Lim HY1, Sun JM1, Ahn JS1, Ahn MJ1, Kim HC6, Sohn TS6, Choi DI7, Cho JH8, Heo JS6, Kwon W6, Uhm SW9, Lee H10, Min BH10, Hong SN10, Kim DH5,11, Jung SH12, Park W4,5, Kim KM2,3, Kang WK1, Park K1,2.
    View PubMed
  • Oncotarget. 2015 Oct 13;6(31):32027-38. doi: 10.18632/oncotarget.5184. Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer Park YH11,2, Shin HT3, Jung HH2, Choi YL3, Ahn T3, Park K3, Lee A4, Do IG5, Kim JY1,2, Ahn JS1, Park WY3, Im YH1,2.
    View PubMed
  • Oncotarget. 2015 Sep 15;6(27):24499-510. Molecular characterization of patients with pathologic complete response or early failure after neoadjuvant chemotherapy for locally advanced breast cancer using next generation sequencing and nCounter assay Park K11, Choi MK2, Jung HH3, Do IG4, Lee KH5, Ahn T1, Kil WH6, Kim SW6, Lee JE6, Nam SJ6, Kim DH7, Ahn JS2, Im YH2,3, Park YH2,3.
    View PubMed
  • J Clin Oncol. 2015 Aug 1;33(22):2450-6. doi: 10.1200/JCO.2014.59.9324. Epub 2015 Jun 29. Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin According to Thymidylate Synthase Expression in Nonsquamous Non-Small-Cell Lung Cancer: A Biomarker-Stratified Randomized Phase II Trial Sun JM11, Ahn JS1, Jung SH1, Sun J1, Ha SY1, Han J1, Park K1, Ahn MJ2.
    View PubMed
  • Cancer Med. 2015 Aug;4(8):1196-204. doi: 10.1002/cam4.471. Epub 2015 Apr 27. Current practices in cancer pain management in Asia: a survey of patients and physicians across 10 countries ACHEON Working Group1, Kim YC1, Ahn JS2, Calimag MM3, Chao TC4,5, Ho KY6, Tho LM7, Xia ZJ8, Ward L9, Moon H10, Bhagat A10.
    View PubMed
  • Breast Cancer Res Treat. 2015 Aug;152(3):675-82. doi: 10.1007/s10549-015-3502-4. Epub 2015 Jul 22. Quantitative changes in skin composition parameters due to chemotherapy in breast cancer patients: a cohort study Kang D11, Kim IR, Im YH, Park YH, Ahn JS, Lee JE, Nam SJ, Park H, Kim E, Lee HK, Lee DY, Cho J.
    View PubMed
  • J Clin Oncol. 2015 Aug 20;33(24):2660-6. doi: 10.1200/JCO.2014.60.0130. Epub 2015 Jul 6. Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04 Ahn JS11, Ahn YC1, Kim JH1, Lee CG1, Cho EK1, Lee KC1, Chen M1, Kim DW1, Kim HK1, Min YJ1, Kang JH1, Choi JH1, Kim SW1, Zhu G1, Wu YL1, Kim SR1, Lee KH1, Song HS1, Choi YL1, Sun JM1, Jung SH1, Ahn MJ1, Park K2.
    View PubMed
  • Breast Cancer Res Treat. 2015 Jul;152(1):77-85. doi: 10.1007/s10549-015-3450-z. Epub 2015 Jun 2. Quality of life (QoL) in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine (PG) chemotherapy: results from phase III, multicenter, randomized trial of maintenance chemotherapy versus observation (KCSG-BR07-02) Park YH11, Jung KH, Im SA, Sohn JH, Ro J, Ahn JH, Kim SB, Nam BH, Oh do Y, Han SW, Lee S, Park IH, Lee KS, Kim JH, Kang SY, Lee MH, Park HS, Woo SY, Jung SH, Ahn JS; Korean Cancer Study Group (KCSG), Im YH.
    View PubMed
  • Support Care Cancer. 2015 Jun;23(6):1769-77. doi: 10.1007/s00520-014-2507-6. Epub 2014 Dec 3. A randomized study of the efficacy and safety of transdermal granisetron in the control of nausea and vomiting induced by moderately emetogenic chemotherapy in Korean patients Kim JE11, Hong YS, Lee JL, Kim KP, Park SJ, Sym SJ, Shin DB, Lee J, Park YS, Ahn JS, Kim TW.
    View PubMed
  • Cancer Chemother Pharmacol. 2015 Jun;75(6):1229-36. doi: 10.1007/s00280-015-2740-9. Epub 2015 Apr 23. A phase II trial of gefitinib monotherapy in pretreated patients with advanced non-small cell lung cancer not harboring activating EGFR mutations: implications of sensitive EGFR mutation test Choi MK11, Hong JY, Chang WJ, Kim MJ, Kim SM, Jung HA, Do IG, Choi YL, Sun JM, Ahn JS, Park K, Ahn MJ.
    View PubMed
  • J Thorac Oncol. 2015 Jun;10(6):903-9. doi: 10.1097/JTO.0000000000000535. The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors Lee JY11, Ku BM, Lim SH, Lee MY, Kim H, Kim M, Kim S, Jung HA, Sun JM, Ahn JS, Park K, Ahn MJ.
    View PubMed
  • Breast. 2015 Jun;24(3):213-7. doi: 10.1016/j.breast.2015.01.012. Epub 2015 Feb 24. Prevalence and clinical outcomes of young breast cancer (YBC) patients according to intrinsic breast cancer subtypes: Single institutional experience in Korea Park YH11, Lee SJ1, Jung HA1, Kim SM1, Kim MJ1, Kil WH2, Lee JE2, Nam SJ2, Ahn JS1, Im YH3.
    View PubMed
  • Int J Cancer. 2015 Apr 15;136(8):1976-84. doi: 10.1002/ijc.29233. Epub 2014 Dec 24. A seven-gene signature can predict distant recurrence in patients with triple- negative breast cancers who receive adjuvant chemotherapy following surgery Park YH11, Jung HH, Do IG, Cho EY, Sohn I, Jung SH, Kil WH, Kim SW, Lee JE, Nam SJ, Ahn JS, Im YH.
    View PubMed
  • Ann Oncol. 2015 Apr;26(4):762-8. doi: 10.1093/annonc/mdu584. Epub 2014 Dec 23. A randomized phase III trial of stereotactic radiosurgery (SRS) versus observation for patients with asymptomatic cerebral oligo-metastases in non-small-cell lung cancer Lim SH11, Lee JY1, Lee MY1, Kim HS1, Lee J1, Sun JM1, Ahn JS1, Um SW2, Kim H2, Kim BS3, Kim ST4, Na DL5, Sun JY6, Jung SH7, Park K1, Kwon OJ2, Lee JI3, Ahn MJ8.
    View PubMed
  • J Breast Cancer. 2015 Mar;18(1):50-6. doi: 10.4048/jbc.2015.18.1.50. Epub 2015 Mar 27. Proportion and Clinical Outcomes of Postoperative Radiotherapy Omission after Breast-Conserving Surgery in Women with Breast Cancer Yu JI11, Choi DH1, Huh SJ1, Park W1, Nam SJ2, Kim SW2, Lee JE2, Kil WH2, Im YH3, Ahn JS3, Park YH3.
    View PubMed
  • Pharmacogenomics. 2015;16(4):383-91. doi: 10.2217/pgs.15.14. Correlation of genetic polymorphisms with clinical outcomes in pemetrexed-treated advanced lung adenocarcinoma patients Woo HI11, Kim JA, Jung HA, Kim KK, Lee JY, Sun JM, Ahn JS, Park K, Lee SY, Ahn MJ.
    View PubMed
  • Invest New Drugs. 2015 Feb;33(1):12-21. doi: 10.1007/s10637-014-0163-9. Epub 2014 Oct 25. BYL719, a selective inhibitor of phosphoinositide 3-Kinase alpha, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer Ku BM11, Jho EH, Bae YH, Sun JM, Ahn JS, Park K, Ahn MJ.
    View PubMed
  • Tumour Biol. 2015 Feb;36(2):1073-9. doi: 10.1007/s13277-014-2730-2. Epub 2014 Oct 19. Prognostic relevance of biological subtype overrides that of TNM staging in breast cancer: discordance between stage and biology Jung HA11, Park YH, Kim M, Kim S, Chang WJ, Choi MK, Hong JY, Kim SW, Kil WH, Lee JE, Nam SJ, Ahn JS, Im YH.
    View PubMed
  • Ann Oncol. 2015 Jan;26(1):161-6. doi: 10.1093/annonc/mdu504. Epub 2014 Oct 29. Small-cell lung cancer detection in never-smokers: clinical characteristics and multigene mutation profiling using targeted next-generation sequencing Sun JM11, Choi YL2, Ji JH3, Ahn JS1, Kim KM2, Han J2, Ahn MJ1, Park K4.
    View PubMed
  • Cancer Chemother Pharmacol. 2014 Sep;74(3):521-9. doi: 10.1007/s00280-014-2542-5. Epub 2014 Jul 22. Clinicopathological features of early failure of neoadjuvant chemotherapy in locally advanced breast cancer Choi MK11, Park YH, Kil WH, Lee JE, Nam SJ, Ahn JS, Im YH.
    View PubMed
  • Oncology. 2014;86(5-6):279-88. doi: 10.1159/000362281. Epub 2014 Jun 4. Validation and Comparison of CS-IHC4 Scores with a Nomogram to Predict Recurrence in Hormone Receptor-Positive Breast Cancers Park YH11, Im SA, Cho EY, Ahn JH, Woo SY, Kim S, Keam B, Lee JE, Han W, Nam SJ, Park IA, Noh DY, Yang JH, Ahn JS, Im YH.
    View PubMed
  • Oncologist. 2014 Jul;19(7):702-3. doi: 10.1634/theoncologist.2013-0419. Epub 2014 May 27. Phase II Study of Afatinib as Third-Line Treatment for Patients in Korea With Stage IIIB/IV Non-Small Cell Lung Cancer Harboring Wild-Type EGFR Ahn MJ11, Kim SW2, Cho BC3, Ahn JS1, Lee DH2, Sun JM4, Massey D5, Kim M6, Shi Y7, Park K8.
    View PubMed
  • Cancer Chemother Pharmacol. 2014 Jun;73(6):1217-25. doi: 10.1007/s00280-014-2458-0. Epub 2014 Apr 3. Safety and efficacy of gemcitabine or pemetrexed in combination with a platinum in patients with non-small-cell lung cancer and prior interstitial lung disease Choi MK11, Hong JY, Chang W, Kim M, Kim S, Jung HA, Lee SJ, Park S, Chung MP, Sun JM, Park K, Ahn MJ, Ahn JS.
    View PubMed
  • Ann Surg Oncol. 2014 Jun;21(6):2083-90. doi: 10.1245/s10434-014-3540-x. Epub 2014 Feb 13. Pretreatment Clinical Mediastinal Nodal Bulk and Extent do not Influence Survival in N2-Positive Stage IIIA Non-small Cell Lung Cancer Patients Treated with Trimodality Therapy Lee H11, Ahn YC, Pyo H, Kim B, Oh D, Nam H, Lee E, Sun JM, Ahn JS, Ahn MJ, Park K, Choi YS, Kim J, Zo JI, Shim YM.
    View PubMed
  • Cancer Chemother Pharmacol. 2014 May;73(5):1063-70. doi: 10.1007/s00280-014-2442-8. Epub 2014 Mar 25. Is there any predictor for clinical outcome in EGFR mutant NSCLC patients treated with EGFR TKIs Lee JY11, Lim SH, Kim M, Kim S, Jung HA, Chang WJ, Choi MK, Hong JY, Lee SJ, Sun JM, Ahn JS, Park K, Ahn MJ.
    View PubMed
  • Cancer Res Treat. 2014 Apr;46(2):200-3. doi: 10.4143/crt.2014.46.2.200. Epub 2014 Apr 22. Intra-tumoral Metastatic Double Primary Carcinoma: Synchronous Metastatic Tumor in Lung from Breast and Thyroid Carcinoma Park LC11, Jeong JY2, Ji JH3, Park S3, Ahn JS3, Im YH3, Park YH3.
    View PubMed
  • Cancer Res Treat. 2014 Apr;46(2):131-40. doi: 10.4143/crt.2014.46.2.131. Epub 2014 Apr 22. A Nationwide Survey of Knowledge of and Compliance with Cancer Pain Management Guidelines by Korean Physicians Kim do Y11, Ahn JS2, Lee KH3, Kim YC4, Lee J5, Kim SY6.
    View PubMed
  • J Thorac Oncol. 2014 Apr;9(4):506-11. doi: 10.1097/JTO.0000000000000095. Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non-Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor Receptor Mutation in Either Exon 19 or 21 Lim SH11, Lee JY, Sun JM, Ahn JS, Park K, Ahn MJ.
    View PubMed
  • Lung Cancer. 2014 Apr;84(1):51-5. doi: 10.1016/j.lungcan.2014.01.017. Epub 2014 Jan 28. A retrospective comparison of adjuvant chemotherapeutic regimens for non-small cell lung cancer (NSCLC): Paclitaxel plus carboplatin versus vinorelbine plus cisplatin Chang WJ11, Sun JM2, Lee JY1, Ahn JS1, Ahn MJ1, Park K1.
    View PubMed
  • Support Care Cancer. 2014 Mar;22(3):741-50. doi: 10.1007/s00520-013-2030-1. Epub 2013 Nov 8. A prospective, open-label, multicenter study of the clinical efficacy of extended-release hydromorphone in treating cancer pain inadequately controlled by other analgesics Han HS11, Lee KH, Lee KH, Ryu JS, Kim YC, Park SW, Oh HS, Park KT, Kwon JH, Lee PB, Lee WS, Kim YS, Ahn JB, Jeon SW, Lee SY, Seol YM, Kang JH, Yuh YJ, Oh SY, Kim SR, Ahn JS.
    View PubMed
  • Eur J Cancer. 2014 Mar;50(4):698-705. doi: 10.1016/j.ejca.2013.11.028. Epub 2013 Dec 18. Genetic polymorphisms of SLC28A3, SLC29A1 and RRM1 predict clinical outcome in patients with metastatic breast cancer receiving gemcitabine plus paclitaxel chemotherapy Lee SY11, Im SA2, Park YH3, Woo SY4, Kim S4, Choi MK5, Chang W5, Ahn JS5, Im YH5.
    View PubMed
  • Lung Cancer. 2014 Feb;83(2):259-64. doi: 10.1016/j.lungcan.2013.11.009. Epub 2013 Nov 20. Clinical characteristics associated with ALK rearrangements in never-smokers with pulmonary adenocarcinoma Sun JM11, Lira M2, Pandya K2, Choi YL3, Ahn JS1, Mao M2, Han J3, Park K1, Ahn MJ4, Kim J5.
    View PubMed
  • J Clin Oncol. 2014 Jan 10;32(2):121-8. doi: 10.1200/JCO.2013.50.8556. Epub 2013 Dec 9. Integrative and Comparative Genomic Analysis of Lung Squamous Cell Carcinomas in East Asian Patients Kim Y11, Hammerman PS, Kim J, Yoon JA, Lee Y, Sun JM, Wilkerson MD, Pedamallu CS, Cibulskis K, Yoo YK, Lawrence MS, Stojanov P, Carter SL, McKenna A, Stewart C, Sivachenko AY, Oh IJ, Kim HK, Choi YS, Kim K, Shim YM, Kim KS, Song SY, Na KJ, Choi YL, Hayes DN, Kim J, Cho S, Kim YC, Ahn JS, Ahn MJ, Getz G, Meyerson M, Park K.
    View PubMed
  • Br J Cancer. 2014 Jan 21;110(2):384-91. doi: 10.1038/bjc.2013.757. Epub 2013 Dec 17. Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) who received taxane plus trastuzumab treatment Park YH11, Jung HA1, Choi MK1, Chang W1, Choi YL2, Do IG2, Ahn JS1, Im YH1.
    View PubMed
  • Lung Cancer. 2013 Dec;82(3):455-60. doi: 10.1016/j.lungcan.2013.08.027. Epub 2013 Sep 8. A randomized, phase II study of vandetanib maintenance for advanced or metastatic non-small-cell lung cancer following first-line platinum-doublet chemotherapy Ahn JS11, Lee KH, Sun JM, Park K, Kang ES, Cho EK, Lee DH, Kim SW, Lee GW, Kang JH, Lee JS, Lee JW, Ahn MJ.
    View PubMed
  • Lung Cancer. 2013 Aug;81(2):231-5. doi: 10.1016/j.lungcan.2013.04.011. Epub 2013 May 14. The optimal duration of vitamin supplementation prior to the first dose of pemetrexed in patients with non-small-cell lung cancer Kim YS11, Sun JM, Ahn JS, Ahn MJ, Park K.
    View PubMed
  • Ann Oncol. 2013 Jun;24(6):1485-90. doi: 10.1093/annonc/mds658. Epub 2013 Feb 4. Multicentre phase II trial of bevacizumab combined with docetaxel-carboplatin for the neoadjuvant treatment of triple-negative breast cancer (KCSG BR-0905) Kim HR11, Jung KH, Im SA, Im YH, Kang SY, Park KH, Lee S, Kim SB, Lee KH, Ahn JS, Kim SI, Sohn JH.
    View PubMed
  • J Mol Diagn. 2013 Jan;15(1):51-61. doi: 10.1016/j.jmoldx.2012.08.006. Epub 2012 Dec 12. Multiplexed Gene Expression and Fusion Transcript Analysis to Detect ALK Fusions in Lung Cancer Lira ME11, Kim TM, Huang D, Deng S, Koh Y, Jang B, Go H, Lee SH, Chung DH, Kim WH, Schoenmakers EF, Choi YL, Park K, Ahn JS, Sun JM, Ahn MJ, Kim DW, Mao M.
    View PubMed
  • J Breast Cancer. 2012 Jun;15(2):239-43. doi: 10.4048/jbc.2012.15.2.239. Epub 2012 Jun 28. Survey of the Application of the Korean Clinical Practice Recommendations on Breast Cancer Treatment: The Utility of the Korean Breast Cancer Society Guidelines Gwak G11, Lee HK, Kim HJ, Lee SY, Park YL, Lee JW, Kim SG, Huh H, Shin H, Kim JR, Ahn JS, Son JH, Lee IG, Park WC, Kim SY, Han S, Lee ES; Korean Breast Cancer Society; Korea Breast Cancer Foundation.
    View PubMed
  • Breast Cancer Res Treat. 2012 Apr;132(2):589-600. doi: 10.1007/s10549-011-1852-0. Epub 2011 Nov 18. Phase II trial of preoperative paclitaxel, gemcitabine, and trastuzumab combination therapy in HER2 positive stage II/III breast cancer: The Korean Cancer Study Group BR 07-01 Im SA11, Lee KS, Ro J, Lee ES, Kwon Y, Ahn JH, Ahn JS, Kim JH, Kang HS, Shin KH, Noh DY, Park IA, Kim SB, Im YH, Ha SW.
    View PubMed
  • J Clin Oncol. 2012 Apr 1;30(10):1122-8. doi: 10.1200/JCO.2011.36.8456. Epub 2012 Feb 27. First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung Han JY11, Park K, Kim SW, Lee DH, Kim HY, Kim HT, Ahn MJ, Yun T, Ahn JS, Suh C, Lee JS, Yoon SJ, Han JH, Lee JW, Jo SJ, Lee JS.
    View PubMed
  • Support Care Cancer. 2010 Feb;19(2):297-301. doi: 10.1007/s00520-010-0825-x. Epub 2010 Mar 7. The dosing frequency of sustained-release opioids and the prevalence of end-of-dose failure in cancer pain control: a Korean multicenter study Kim DY11, Song HS, Ahn JS, Ryoo BY, Shin DB, Yim CY, Kim SY.
    View PubMed
  • Breast Cancer Res Treat. 2011 Jan;125(1):99-106. doi: 10.1007/s10549-010-1201-8. Epub 2010 Oct 5. Zoledronic acid prevents bone loss in premenopausal women with early breast cancer undergoing adjuvant chemotherapy: a phase III trial of the Korean Cancer Study Group (KCSG-BR06-01) Kim JE11, Ahn JH, Jung KH, Kim SB, Kim HJ, Lee KS, Ro JS, Park YH, Ahn JS, Im YH, Im SA, Lee MH, Kim SY.
    View PubMed
  • Lung Cancer. 2011 Jan;71(1):89-93. doi: 10.1016/j.lungcan.2010.04.003. Epub 2010 Jul 3. Predictors of skeletal-related events in non-small cell lung cancer patients with bone metastases Sun JM11, Ahn JS, Lee S, Kim JA, Lee J, Park YH, Park HC, Ahn MJ, Ahn YC, Park K.
    View PubMed
  • BMC Cancer. 2010 Oct 5;10:527. doi: 10.1186/1471-2407-10-527. Favorable response to doxorubicin combination chemotherapy does not yield good clinical outcome in patients with metastatic breast cancer with triple-negative phenotype Yi SY11, Ahn JS, Uhm JE, Lim do H, Ji SH, Jun HJ, Kim KH, Chang MH, Park MJ, Cho EY, Choi YL, Park YH, Im YH.
    View PubMed
  • Lung Cancer. 2010 Sep;69(3):323-9. doi: 10.1016/j.lungcan.2009.12.002. Epub 2010 Jan 12. The efficacy of pemetrexed as a third- or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung cancer Chang MH11, Ahn JS, Lee J, Kim KH, Park YH, Han J, Ahn MJ, Park K.
    View PubMed
  • Ann Hematol. 2010 Jul;89(7):725-31. doi: 10.1007/s00277-010-0910-8. Epub 2010 Feb 24. Phase IV study evaluating efficacy of escalated dose of imatinib in chronic myeloid leukemia patients showing suboptimal response to standard dose imatinib Koh Y11, Kim I, Yoon SS, Kim BK, Kim DY, Lee JH, Lee KH, Park E, Kim HJ, Sohn SK, Joo YD, Kim SJ, Chung J, Shin HJ, Kim SH, Kim CS, Song HS, Kim MK, Hyun MS, Ahn JS, Jung CW, Park S; Korean Society of Hematology CML working party.
    View PubMed
  • Cancer. 2010 Jan 1;116(1):132-6. doi: 10.1002/cncr.24719. Multicenter Phase 2 Study of Belotecan, a New Camptothecin Analog, and Cisplatin for Chemotherapy-Naive Patients With Extensive-Disease Small Cell Lung Cancer Lee DH11, Kim SW, Suh C, Lee JS, Ahn JS, Ahn MJ, Park K, Na II, Lee JC, Ryoo BY, Yang SH.
    View PubMed
  • Oncology.?2008;74 Suppl 1:4-6. doi: 10.1159/000143211. Epub 2008 Aug 28. Progress of cancer pain management in Korea Lee JY11,?Ahn JS.
    View PubMed